CURRICULUM VITAE IDENTIFICATION - … VITAE IDENTIFICATION Jacques Genest MD FRCP(C) Scientific...

CURRICULUM VITAE IDENTIFICATION Jacques Genest MD FRCP(C) Scientific Director, Center for Innovative medicine, McGill University Health Center Research Institute Professor, Department of Medicine, McGill University McGill – Novartis Chair in Medicine McGill University Health Center/Royal Victoria Hospital M4.72 687 Pine avenue West Montreal, QC Canada H3A 1A1 Tel: (514) 934-1934 ext 34630 Fax: (514) 843-2813 E-mail: [email protected] Born: May 20th, 1957 Montréal, CANADA Citizenship: Canadian Married, two children: Geneviève and Madeleine EDUCATION Degree Year Field of Study Collège Stanislas Bacc. 1975 Sciences McGill University MD CM 1980 Medicine Royal Victoria Hospital 1980-81 Internship Royal Victoria Hospital FRCP(C) 1981-84 Medicine Tufts University, Boston FRCP(C) 1984-86 Cardiology Fellow, Epidemiology and Prevention of Cardiovascular , Diseases, 1985 CA Tufts University, Boston Post-Doc 1986-90 Molecular Genetics & Lipid Metabolism Licensure 1981- Medical Council of Canada 1981- Corporation professionnelle des médecins du Québec Lic # 1814722 1981- Royal College of Physicians and Surgeons of Canada Lic # 340504 1982- National Board of Medical Examiners 1985- Internal Medicine, FRCP (Canada) 1985- Médecin Spécialiste, Médecine Interne, CPMQ Lic # 10315 1987- Cardiology, FRCP (C) 1987- Médecin Spécialiste, Cardiologie, Québec Lic # 11268 APPOINTMENTS 1982-1984 Clinical Instructor, Medicine, Royal Victoria Hospital 1984-1986 Clinical Instructor, Medicine, Tufts-New England Medical Center, Boston 1986-1987 Junior Attending Physician, Cardiology Service, New England Medical Center Hospital 1987-1988 Cardiology Consultant, Cardiology Service, New England Medical Center Hospital 1987-1990 Staff Cardiologist, Lakeshore General Hospital, Montréal, Québec, Canada 1989-2000 Consultant, Montréal Heart Institute, Montréal, Canada 1990-2000 Staff Cardiologist, Hôpital Hôtel-Dieu de Montréal, Canada 1990-1991 Senior Researcher, Clinical Research Institute of Montréal 1991-1992 Assistant Researcher, Université de Montréal 1991-2000 Director, Cardiology/Prevention Clinic, Clinical Research Institute of Montréal 1992-2000 Director, Cardiovascular Genetics Laboratory, Clinical Research Institute of Montréal 1996-2000 Staff Cardiologist, Centre Hospitalier de l'Université de Montréal 1996-2000 Associate Professor, Department of Medicine, Université de Montreal 1998-2000 Adjunct Professor, Department of Medicine, McGill University 2000 Associate Professor of Medicine, McGill University, Department of Medicine

Jacques Genest MD Curriculum Vitae 3/25/2012

2

2000-2010 Head of Cardiology, McGill University, Chief, Division of Cardiology, McGill University Health Center

2000-present Professor, Department of Medicine, McGill University 2001-present Associate Member, Department of Human Genetics McGill University 2006-present Associate Member, Department of Biochemistry, McGill University 2010-present Scientific Director, Center for Innovative Medicine, McGill University Health Center Honors and Awards 1975 College Stanislas. Biology and Communication Prizes 1999 Prix “Marcel Piché” for excellence in research, Clinical Research Institute of Montréal 2000 I. W. Beaton Fellowship in Cardiology, McGill University 2001 Senior Scientist Award, Canadian Lipoprotein Conference, NS 2003 Distinguished Physician Scientist Lecture, Canadian Lipoprotein Conference. 2006 Heart and Stroke Foundation Club Lions de Buckingham / Robert Champagne Award 2006 Bristol-Myers – Squibb / Sanofi-aventis Awars in Cardiology -McGill University 2008 Sharron Axler Feifer Award of Excellence, Fondation des Maladies du Coeur du Québec 2009 Fondation des Maladies du Cœur (Québec) / Pfizer Award of Excellence 2011 Margolese National Brain and Heart Disorders Prize (Inaugural). U British Columbia 2011- Elected Fellow in the Canadian Academy of Health Sciences (CAHS) Fellowships and Chairs 1975 Meakins-Christie Laboratory Summer Student, McGill University 1986-9 Medical Research Council of Canada, Centennial Fellowship (3 years) 1989 Medical Research Council of Canada, Research Fellowship (1 year) 1991-2 Fonds de la recherche en santé du Québec. Clinicien-Chercheur Scholarship (1 year) 1991 Heart and Stroke Foundation of Canada, Scholarship (declined) 1992-7 Medical Research Council of Canada, Scholarship 1992- (5 years) 1992 Fonds de la recherche en santé du Québec. Clinicien-Chercheur Scholarship (declined) 1997-00 Fonds de la recherche en santé du Québec. Clinical Scientist Senior I, salary award 2000-4 Chercheurs Nationaux, Fonds de la recherche en santé du Québec (FRSQ) 2000-5 McGill-Novartis Chair in Medicine, Department of Medicine, McGill University (5 years) 2001 CIHR Chair (CIHR-Industry program, Novartis) 2005-10 McGill-Novartis Chair in Medicine, Department of Medicine, McGill University; renewed 5 years 2010-15 McGill-Novartis Chair in Medicine, Department of Medicine, McGill University; renewed 5 years Societies 1987 Member, Canadian Lipoprotein Conference 1988- Member, Canadian Cardioascular Society 1989 Fellow, American College of Cardiology (FACC) 1989 Member, Canadian Society of Atherosclerosis, Thrombosis and Vascular Biology 2001 Fellow, American Heart Association Council on Atherosclerosis, Thrombosis and Vascular Biology 2008- Member, American Society for Biochemistry and Molecular Biology (ASBMB) TEACHING Other Courses • Pharmacology of lipid-lowering agents, Université de Montréal 1990,91,92,93,94,96 • Residents Rounds, Hôpital Hôtel-Dieu de Montréal 1991, 92, 93, 94, 95, 96, 98, 99 • Cardiology Rounds, Cardiology Services, Hôpital Hôtel-Dieu de Montréal, 1992 to 1999 • Post graduate clinical teaching, Internal Medicine and Cardiology, Medicine residents, Université de Montréal

Medical School, 1991-present (8-10 weeks/year, as part of ward responsibilities). • Continuous Medical Education activities: approximately 5-10 CME accredited courses per year to general

practitioners and specialists. • Internal Medical Resident teaching course on lipoprotein metabolism Université de Montréal. 1997, 98, 99,

2000 • Journées du Département de médecine, Université de Montréal. Secondary prevention of cardiovascular

diseases. Nov 1997


3

• Journées du Département de médecine, Université de Montréal. Hyperlipidemias. Dec 1998 • Journées du Département de pharmacologie, Université de Montréal. Canadian Guidelines for the diagnosis

and treatment of dyslipidemias, May 1999 • Graduate course PCB 6041, Pathobiology of Vascular Disease. Université de Montréal, 2000 (3 hours) • Graduate course BCM 6151. Protein and Biological Liquids in Humans. Université de Montréal .

Apolipoproteins 1998, 2000 (3 hours) • Université de Montréal, Biochemistry of Apolipoproteins BCM 6151 1997; BCM 6041 2000

McGill Courses

• McGill University NEUR 550 graduate course: Oxidation and Vascular diseases, 2004, 05, 06 • Biochemistry course on Lipoprotein metabolism. McGill University, 1991, 1992, 1993, 1994, 1995 • McGill University Medical School Curriculum Cardiovascular Physiology 2001-3 • McGill Genetics 177-575. Graduate course, Department of Human Genetics, McGill University. Medical

Biochemical Genetics. Disorders of lipoprotein metabolism (4.5 hours; 12 hours preparation) 2002, 03, 04, 05, 06, 07, 08, 09, 10, 11

• Physiology 516-506B: Advanced Cardiovascular Physiology, McGill University Disorders of lipoproteins and CAD. 2002, 03, 04, 05, 06, 07, 08, 09, 10, 11 (3 hours; 10 hours preparation)

• Medicine INDS 208 Unit 8 (Med2-) McGill University Medical School “Genetics of Coronary Artery Disease”, 2002, 03, 04, 05, 06, 07, 08, 09, 10, 11 (2 hours; 4 hours preparation)

• BIOC570: McGill University department of Biochemistry graduate course (Biochemistry of Lipids) 2011 (2 hours; 4 hours preparation)

Clinical Teaching Medical Students, Clinical: Third, fourth and fifth year medical student teaching on clinical rotations in cardiology at Hôpital Hôtel-Dieu

de Montréal. Approximately 5 hours/week, 10 weeks per year. Subjects: physical examination in cardiology, emergency cardiac care, ECG interpretation, clinical cardiology.

Medical Residents, Clinical:

• First and second year medical residents from Université de Montréal on clinical rotations in cardiology at Hôpital Hôtel-Dieu de Montréal. Approximately 10 hours/week, 10 weeks per year. Subjects: physical examination in cardiology, emergency cardiac care, ECG interpretation, clinical cardiology.

• Pharmacology of lipid-lowering drugs, Medical Residents 3 hours/year, 1991,92,93,94,97,98 • Cardiology Residents Teaching, Epidemiology of Coronary Artery Disease, 1998, 99 • McGill University Health Centre. Clinical cardiology teaching, 10 hours/week, 8-10 weeks per year. Research Trainees and Summer students

Lina KARAYAN BSc 1991 (June-November), 1992 (June-August) Valerie LAFRAMBOISE 1994 (Research elective) Elisabeth RESS 1994 (Summer student) Marie WEBER 1995 (Summer student) Luna GRISEL 1995 (Summer student) Vincent JEROME 1995 (Summer student) Jean GRONDIN BSc 1996 (Student) Line TREMBLAY 1995-96 (Masters student) Martine COTE 1997 (Research elective) Rachel BISSONNETTE BSc 1998 (Summer student) Ching Yin LEE 2000 (Summer student)

John HILTON 2002 (Summer student) Jerome VINCENT DES 2002-3 (Research Associate) Marilyn CARRIER 2002-3 (Research Elective) Isabelle RUEL MSc 2003 (Student) Sasha BLAIN 2004 (Summer Student) Carole DANGOISSE BSc 2004 (Summer Student) Haley COCHRANE BSc 2006 (Summer Student)


4

Doris DU 2006 (Summer Student) Sarah ALAJAMI 2006 (Summer Student) Steve CAMPBELL 2008 (Summer Student–McGill Biochem 491) Safia CHATUR 2008 (Summer Student –McGill Biochem 491) Genevieve GENEST BSc 2008 (Summer student, U de M) Jordan DOHERTY 2010 BIOC 491 Steve CAMPBELL 2010 (Biology elective); Aurelien PALMYRE 2011 (Universite de Paris)

Masters students Stephanie MOTTS 1996-98 MSc

Maxim DENIS BSc 1997-99 MSc 1999 Rachel BISSONNETTE BSc 2000-2 MSc 2002 Donna LEE 2006-8[10] Iulia IATAN 2007-9 [9] Dana NYHOLT 2006-8 (Co-supervision) Steve CAMPBELL 2010 (Biochemistry, McGill) Sarah ALRASHEED 2010- [14] Bashar JABOR 2011- Doctoral Students Michel MARCIL MSc 1993-1998 PhD 2000 Dean's Honor list [1] Bassam HAIDAR MSc 1998-2003 PhD 2003 Maxime DENIS MSc 1999-2004 PhD 2004 Dean`s Honor list [3] Brian O’CONNELL 2000-2004 (MD-PhD 2007)[2] Ching Yin LEE 2001-2006 PhD 2007 [4][β][η] Zari DASTANI 2003-2009 PhD 2009 [χ][5][7] Houssein Hajj HASSAN 2004-2007 PhD 2011 [6][ε] Dana BAILEY 2007-2011 PhD 2011 [8][12][γ] Iulia IATAN 2008- [11][φ][13][ι][υ]

[1] These selected as best doctoral thesis for Montreal Universities 1999. Academie des Grands Montrealais, Jun 2000 [2] Funded, CIHR MD/PhD program, McGill University [3] Funded, studentship, HSFC 2000 [4] Funded, MUHC Research Institute; FRSQ (2004) and HSFC (2004) studentship [5] Funded, MUHC Research Institute [6] Funded, Student bursary, Université de Monréal [7] Funded, HSFC (2006) studentship [8] Funded NSERC (2007-9) [9] Funded, MUHC Research Institute [10] Funded, MUHC Research Institute [11] Funded, FRSQ 2008-11 [12] Vanier Doctoral Research Award CIHR 2009 [13] Banting and Best Doctoral Research Scholarship CIHR 2009-12 [14] Funded, Saudi Arabia

[α] First Prize, Students competition, Canadian Lipoprotein Conference, Oct 1999; [β] First Prize, Students competition, Canadian Lipoprotein Conference, Oct 2004; [χ] Research award, Students competition, Cardiovascular Axis Research Day, McGill Feb 2005 [η] Research award, Students competition, Cardiovascular Axis Research Day, McGill Feb 2006 [ε] Canadian Lipoprotein Conference best Poster Award 2006 [φ] Canadian Lipoprotein Conference best Poster Award 2008 [γ] Canadian Lipoprotein Conference best oral presentation 2009 [ι] Selected as one of the 10 best presentations, ATVB meeting April 2010 [ι] IAS HDL Workshop, Whistler BC, Best Poster Award 2010

[υ] Canadian Lipoprotein Conference best oral presentation 2009


5

Post-doctoral Fellows (Basic) ShiQuiang QIU MD 1991-94 (Post-doctoral training) Lu YU MD 1993-99 (Post-doctoral training) Stephanie MOTT 1996-97 (Post-doctoral training) Xiaoduan WENG MD 1996-98 (Post doctoral fellow) Michel MARCIL PhD 1999-00 (Post-doctoral training) [1]

Louise-Marie GIROUX PhD 2000-01 Larbi KRIMBOU MSc 2002-03 (PDF) Shirya RHASHID 2005- (Post doctoral fellow) [2] [1] Fellowship salary award, McGill University Health Center, 2000-4 [2] CIHR post-doctoral fellowship 2005-6

Research Assistants, Associates Michel Marcil PhD 2001-03 Larbi Krimbou DES 2005-11 Isabelle Ruel PhD 2005-

Post-doctoral Fellows (Clinical)

Serge McNICOLL MD 1994-95 (Research Elective) Ngoc-Huu NGUYEN MD 1994-95 (Research elective) Karl DALERY MD 1994-95 (Research elective) First Prize, Residents Res

Eva WESOLOWSKA MD 1994-97 (Post-doctoral training) Quan HUAN MD 1996-98 (Research elective) Vicky SOULIERE MD 1997-98 (Resident I) (Post-doctoral fellow) Marie-Chantale AUDELIN 1999-00 (Resident II, Research elective) Jean-François DORVAL 2003-04 (Resident I, Research elective)

Mohamed ALUN 2002-04 (Resident I, Internal Medicine) Muhamed AL-ANEZI 2002-03 (Resident IV, medical biochemistry) Maha ALAMRI 2004 (Resident IV, medical biochemistry) Khalid ALRASADI 2004-05 (Resident IV, medical biochemistry) Mamhoud ALAWADHI 2004-05 (Resident IV, Endocrinology) George THANASSOULIS 2004-05 (Resident IV, Cardiology) Khalid ALRASADI 2006-07 (Resident VI, medical biochemistry) Zuhier AWAN 2006-07 (Resident V, medical biochemistry) Khalid ALWAILI 2007-08 (Resident V, medical biochemistry) Jacqueline JOZA 2008- (Resident I, Internal Medicine) Zuhier AWAN 2008-09 (Resident VI, medical biochemistry) Khalid ALWAILI 2008-10 (Resident VI, medical biochemistry) Ali ALASHERANI 2011-12 (Resident III, Internal Medicine)

Graduate students thesis committee Alain Baldo, Ph.D. McGill University, 1993-4 Xao Zeng McGill University, 1995-6 Robert Moreau Université de Montréal, thesis advisory committee 1995- Magda Maslowska Concordia University, 1996- Angelica Fleser Université de Montréal, 1996- Marie-Claude Vohl Université Laval Ph.D. thesis external reviewer 1996. Xiao-Jing Zhang McGill University, Ph.D. advisory committee 1996- Mohamed El Mambrouk Université de Montréal, Ph. D. Reviewer 1997 Caroline Marcoux Université de Montréal Ph. D. Advisory committee, 1998-2000

May Faraj McGill University, Ph.D. advisory committee 2000-3 Eric Hyndman University of Alberta Ph. D.External examiner 2000 Oana-Maria Nicolescu McGill University. Master’s Thesis Ext. reviewer 2001 Nicolas Boussette McGill University, PhD Committee, 2003-6. PhD dec 2006 Ramin Zargham Université de Montréal, PhD Committee, 2005- Sophie Charbonneau McGill University, Dept. Experimental Medicine 2006


6

Guillaume Paré Université de Montréal, Medical Biochemistry program 2006 Dana Nyholt McGill University, Experimental Medicine 2006- Iulia Iatan McGill University, Experimental Medicine 2007-8 Donna Lee McGill University, Experimental Medicine 2007-8 Dana Nyholt McGill University, dept. Biochemistry 2008 Iulia Iatan McGill University, dept. Biochemistry 2008 Catie Lichten McGill University, Physiology Dept 2008 Ron DO McGill Univesity, Department of Human Genetics 2008- Luna grizel Universite de Montreal, dept. Biochemistry 2009- Andrew Dawson McGill University, Experimental Medicine 2010 Kevin W. Johns. University of British Columbia. External examiner 2011 Brie Sorrenson, University of Otago, New Zeland, External examiner 2011 Zuhier Awan, Universite de Montreal (Co-supervision) Committee member 2011- Robert J Doonan, McGill University, Experimental Medicine 2011-

Recruitment at McGill University Dr. James Brophy 2002 Cardiologist, Head of the McGill Technology Assessment Unit Dr. Jean Buithieu 2002 Cardiologist, Director, non-invasive cardiology MUHC Dr. Jean-Phillipe Pelletier 2005 Cardiologist, Interventional Cardiology Dr. Vidal Essebag 2006 Cardiologist, Interventional electrophysiology Dr. Giusseppe Martucci 2006 Cardiologist, Interventional and congenital cardiology Dr. Manu Prabhakar 2006 Cardiologist, Interventional Cardiology Dr. Vivian Nguyen 2006 Cardiologist, Heart failure, Director, CCU Dr. Nathalie Bottega 2007 Cardiologist, Congenital Heart Disease Dr. George Thanassoulis 2010 Cardiologist, Clinical and Genetics Dr. Luc Bilodeau 2010 Cardiologist, Interventional Cardiology Dr. Sonny Dandona 2010 Cardiologist, Interventional Cardiology, Genetics Dr. Nicolo Piazza 2011 Cardiologist, Interventional Cardiology Dr. Michel Marcil PhD 2004-8 Medical Scientist Larbi Krimbou DES 2005-11 Medical Scientist Dr. James Engert PhD 2003 Director, Genetics/cardiology laboratory Dr. Scott R. Kiss PhD 2006 Director, Mol. Physiol. Lipid transport laboratory


7

Invited Lectures (Named Lectures) • AHA (New Hampshire) Hyperlipidemias - May 1986 • Massachusetts Heart Association. Hyperlipidemias - October 1987 • Tufts University, Boston CME: Hyperlipidemias - May 1987 • Tufts University, Boston CME: Cardiac Emergencies, Tamponade - August 1987 • Maine Medical Center. Cardiology Rounds: "Diagnosis and Treatment of Hyperlipidemias" - April 1988 • Lakeshore General Hospital. "Hypercholesterolemia: Diagnosis and Treatment" - May 1988 • McGill University, The McGill Conference Workshop on Hypertriglyceridemia and Low HDL - May 1988 • J.B. Thomas Hospital, NH. Medical Grand Rounds, "Update on Cardiovascular Risk Factors" -

September 1988 • Royal Victoria Hospital, Halifax, Nova Scotia, "Hyperlipidemias and Coronary Artery Disease" -

November 1988 • Québec Cardiovascular Society, "Genetic Lipoprotein Abnormalities in Premature CAD" – Jan 1989 • Québec Cardiology Association, "Primary Prevention and Treatment of Lipid Disorders". Québec City,

March 1989 • Medical Grand Rounds, Hôtel Dieu Hospital, Montréal, Canada, "Genetic Lipoprotein Abnormalities in

Premature CAD" - March 1989 • Québec Cardiology Association, Québec, Canada. "Dyslipidemias: Genetics, Diagnosis and

Treatment" - May 1989 • Douglas-Wentworth Hospital, Dover NH. Medical Grand Rounds, "Lipid Disorders; a Review" - June

1989 • Harvard Health Services, Cambridge, MA, "Lipoproteins and Cardiovascular Risk"– September 1989 • Cleveland Clinic, Cleveland, OH. "Lipoprotein Metabolism" - December 1989 • Brown University, Rhode Island Hospital. Endocrinology Rounds, RI, "Genetic Lipid Disorders in

Coronary Artery Disease"- January 1990 • Montréal General Hospital, Montréal, Canada, "Treatment of Lipid Disorders in Patients with CAD",

Health Satellite Teleconference - January 1990 • Maine Medical Center. Lipid Rounds, Portland, ME, "LDL Receptor and Genetic Lipid Disorders" -

February 1990 • Hôpital Notre-Dame de Montréal, Grand Rounds, "Dyslipidémies génétiques chez le coronarien" -

September 1990 • Hôpital Maisonneuve-Rosemont de Montréal, Grand Rounds, "Dyslipidémies génétiques chez le

coronarien" - September 1990 • Toronto General Hospital, Cardiovascular Grand Rounds, "Genetic Dyslipidemias" - October 1990 • Halifax, NS, "Secondary Prevention of Lipid Disorders" - October 1990 • Jewish General Hospital, Montréal. Medical Grand Rounds, "Genetic Lipoprotein Disorders" -

November 1990 • Hopital St-Luc, Montréal. Medical Grand Rounds, "Genetic Lipoprotein Disorders in Coronary Disease

Patients" - December 1990 • Royal Victoria Hospital, Montréal. Cardiology Research Rounds - February 1991 • Hôpital Jean-Talon, Service de médecine, "Régression de la maladie coronarienne" - April 1991 • Ottawa Heart Institute, "Genetics, Lipoproteins, and Cardiovascular Disease" - April 1991 • McGill University Conference on Cardiovascular Risk Factor Interactions. Workshop on

Hypertriglyceridemia. Montréal - June 1991 • IX International Atherosclerosis Conference, Chicago, "The Great Canadian Cholesterol Debate" -

October 1991 • Hôpital Hôtel-Dieu de Montréal, "Lipids and Regression" - October 1991 • Hôpital Sacré Coeur de Montréal, "Lipoproteins and Regression of Coronary Artery Disease" - October

1991 • Lipid Transport Disorder Symposium. Laguna Niguel, CA, "HDL and Atherosclerosis" - November 1991 • Enfant Jesus Hospital, Québec City, Québec, "Genetic Lipoprotein Disorders in CAD" - January 1992 • Hôpital Universitaire de Sherbrooke, Québec, "Genetics and Coronary Artery Disease in French

Canadians" - February 1992 • Hamilton General Hospital, Ontario, "Lipoproteins, Genetics and Coronary Artery Disease" - March

1992 • Hôpital Hôtel Dieu de Québec, "Lipoproteins and Cardiovascular Risk in Renal Disease and

Transplantation" - May 1992


8

• Cardiology Grand Rounds, Baystate Medical Center, Springfield, MA. "Genetic HDL Deficiency in Patients with Coronary Arteriosclerosis" - June 1992

• University of Western Ontario, "Prevention of Coronary Artery Disease" - September 1992 • Medical Grand Rounds, Hôpital Hôtel Dieu de Montréal, "Apolipoprotein B: Genes and Population

Studies" - September 1992 • University of Alberta Hospitals, "Lipoprotein Metabolism" - November 1992 • McGill Conference, Montréal, "Metabolic and Genetic Disorders and CAD" - January 1993 • New York Medical Center, Weschester County, NY, "Metabolic Abnormalities in Coronary Artery

Disease", February 1993 • Tufts University, Boston, MA, "Familial Lipoprotein Disorders in Premature CAD" - March 1993 • Maine Cardiovascular Society Annual Meeting, Lewison, Me, "Familial Hypercholesterolemia in French

Canadians" - April 1993 • Maisonneuve-Rosemont Endocrinology Group, "Genetic Lipoprotein Disorders in Coronary Artery

Disease" June 1993 • McGill University, Department of Medical Genetics, Montreal Children Hospital, "Familial Combined

Hyperlipoproteinemia" - April 1993 • Montreal Heart Institute, Research seminars, "Regulation of the LDL-R and HMG CoA Reductase

Genes in Familial Hypercholesterolemia" - May 1993 • Quebec Cardiology Association, Quebec City. "Genetic Disorders in Premature Coronary Artery

Disease" - October 1993 • Post-Graduate course, Université de Montréal: "Hypertension and Dyslipoproteinemias"- October 1993 • Post-Graduate course, Université de Montréal: "Diagnosis and Treatment of Dyslipoproteinemias" -

November 1993 • Canadian Cardiovascular Society Meeting, Vancouver, Canada. Workshop on "Lipoprotein Disorders

and Coronary Artery Disease"- October 1993 (Workshop Organizer & Speaker) • Symposium on Lipoproteins and Coagulation Factors: Major Risks for Coronary Artery Disease - Boca

Raton, Florida, November 1993 (Co-Chairman) • Hôpital Notre-Dame, Montréal. Cardiology Rounds: "Genetic Predisposition to Coronary Artery

Disease" - November 1993 • University of Toronto, Lipoprotein Conference, Toronto, Canada: "Single Allele Regulation of the LDL-

Receptor and HMG CoA Reductase Gene in Subjects with the "French Canadian" Deletion of the LDL-R Gene" - November 1993

• St Michael's Hospital Lipid Outreach Program, Toronto: "Dyslipidemia and the Heart" - November 1993 • Clinical Research Institute of Montreal, Hyperlipidemia and Atherosclerosis Research Group:

"Homocyst(e)ine and Coronary Artery Disease" - November 1993 • Hôpital Hôtel-Dieu de Montréal. Cardiology Rounds: "Homocyst(e)ine as a Risk Factor in CAD: Role of

Vitamins B6, B12 and Folate" - December 1993 • Centre hospitalier régional de Lanaudière, Cardiology and Nephrology Groups: "Secondary Prevention

of Lipoprotein Disorders" - January 1994 • Hôpital Hôtel-Dieu de Montréal, Medical Grand Rounds: "High density lipoproteins: from epidemiology

to molecular genetics" - March 1994 • Centre hospitalier Universitaire de Sherbrooke, Quebec, Lipid rounds: "Secondary prevention of

cardiovascular diseases" - March 1994 • Hôpital Notre-Dame de Montréal, Research Rounds: "Single allele gene regulation of the LDL-R and

HMG CoA reductase genes" - April 94 • Edmonton and Calgary Lipid groups. "Secondary prevention of cardiovascular diseases" - April 1994 • Hopital Maisoneuve-Rosemont, Montréal: "Renal disease and dyslipoproteinemias" - May 1994 • Western Canada Lipid Specialists meeting, Whistler, Canada: "Secondary prevention of cardiovascular

diseases: the need for a multifactorial approach" - May 1994 • Canadian Association of Clinical Biochemists, Annual Meeting, Québec, Canada: "Homocyst(e)ine in

the prediction of cardiovascular diseases" - June 1994 • University of Calgary Cardiovascular Research Group, Calgary: "Epidemiology and molecular genetics

of high density lipoproteins" - Sept 1994 • IX International atherosclerosis Conference, Montreal, Canada: "Clustering of cardiovascular risk

factors: A clinical perspective" - Oct 1994 • Hôpital Hôtel-Dieu de Montreal, Medical Grand Rounds: "Homocyst(e)ine in Coronary Artery Disease" -

Nov 1994 • Annual conference, Federation des Omnipracticiens du Quebec, Montréal, Canada: "Regroupement

des facteurs de risque dans la MCAS" - Nov 1994


9

• Montreal, Qué. "Results of the Scandinavian Simvastatin Survival Study” - Dec 1994 1995 • Toronto Hospital. Cardiology Grand Rounds: ”HDL deficiency States” - Feb 95 • Credit Valley Hospital, Mississauga, Ont.: ”HDL, Triglycerides and Lp(a) in the prediction of

cardiovascular risk” - Feb 95 • Mount Sinai Hospital, Toronto: ”HDL deficiency states, epidemiology to cell and molecular biology” - Feb

1995 • Toronto Western Hospital: ”HDL deficiency states, epidemiology to cell and molecular biology” - Feb

1995 • Hamilton General Hospital: “Clustering of Cardiovascular Risk Factors” - March 1995 • St Joseph Hospital Endocrine Rounds, London, Ontario: “HDL particles and CAD” - March 1995 • Victoria Hospital Cardiology Grand Rounds, London, Ontario: “Clustering of coronary risk factors” -

March 1995 • Jean Talon Hospital, Montreal: “Lipoprotein disorders in patients with premature CAD” - May 1995 • Newfoundland Lipid Symposium, St. Johns, NFLD: “Secondary Prevention” - May 1995 • Collège des Médecins du Québec, Montréal: “Evaluation and treatment of dyslipoproteinemias” - June

1995 • Québec Cardiologist Association, Chicoutimi: “Secondary prevention of lipoprotein disorders in CAD” -

June 1995 • Hôpital Notre-Dame, Montréal: “Genetics of elevated Homocysteine in premature CAD” - June 1995 • World Congress on Hypertension Control, Ottawa, Canada: “Hypertension and hyperlipidemias” - June

1995 • Cardiac Society of Australia and New Zealand, Annual Meeting, Canberra, Australia: “Genetic

disorders and premature CAD” - Aug 1995 • Australian Atherosclerosis Society, Annual meeting, Canberra, Australia: “Homocysteine and CAD” -

August 1995 • Québec Heart Foundation, Montreal, Québec: “The secondary prevention of coronary artery disease” -

August 1995 • Québec Heart Foundation, Montréal, Québec: “Plasma lipids and coronary artery disease” - Sept 95 • Canadian Cardiovascular Society, Toronto, Ontario. Molecular biology in cardiology workshop: “The

Molecular Genetics of Premature CAD” - October 1995. • Hôpital Notre-Dame, Montréal: “Prevention of cardiovascular disease by lipid lowering agents” - Dec

1995 1996 • Hôpital Hôtel-Dieu de Montréal, Medical Grand Rounds: “Report of the Working Party on

Hypercholesterolemia and other Dyslipidemias - Health Canada” - January 1996 • Hôpital Hôtel-Dieu de Montréal Cardiology Rounds: “Genetic predisposition to coronary artery disease”

- Jan 1996 • Hôpital Hôtel-Dieu de Québec, Medical Grand Rounds, Quebec City: “Homocysteine and CAD: from

epidemiology to molecular genetics” - March 1996 • Centre hospitalier de Sherbrooke: “HDL in the prediction of CAD” - March 1996 • CME, Montreal General Practitioners, Montréal: "New Canadian Guidelines on Diagnosis and

Management of Hypercholesterolemia and other Dyslipidemias" - April 1996 • Montreal General Hospital Cardiology Rounds: “Homocysteine and CAD” - May 1996 • Hôpital Ste-Justine Nephrology Rounds, Montréal: “Hyperhomocysteinemia in renal failure and

cystinosis” - June 1996 • Hopital Maisonneuve-Rosemont Nephrology Rounds, Montreal: “Homocysteine and vascular disease” -

Sept 1996 • IXth International Symposium on Prospective Biology, Eurobiology, Pont-à-Mousson, France:

“Molecular Genetics of Lipoprotein Disorders in Premature Coronary Artery Disease” - Sept 1996 • Hôpital Notre-Dame de Montréal Medical Grand Rounds: “Diagnosis and Treatment of Lipoprotein

Disorders - The Canadian Working Group Report” - Oct 1996. • Frontiers in Lipoprotein Research, American Association of Clinical Chemistry, Dallas Tx

“Homocysteine and Cardiovascular Disease" - Oct 1996. • Second Annual Western Canada Internal Medicine Conference, Banff, Alberta: “Diagnosis and

Treatment of Dyslipidemias” - Oct 1996


10

• St Paul Medical Center Atherosclerosis Specialized Laboratory, Vancouver, BC: “Homocysteine and CAD” - Oct 1996

• St Paul Medical Center Pathology Rounds, Vancouver, BC: “Homocysteine and CAD” - Oct 1996 • Canadian Cardiovascular Society Meeting, Montréal, QC: "The Great Canadian Cholesterol Debate" -

Nov 1996 • Canadian Cardiovascular Society Meeting, Montréal, Qc: “Targeting the high-risk individual and the

coronary patient: redefining goals and optimizing therapy in a cost conscious society” - Nov 1996 • Canadian Association of Cardiovascular Rehabilitation, Montréal, QC: “Treatment and management of

dyslipoproteinemias in the CAD patient” - Nov 1996 • Fédération des Omnipracticiens du Québec Annual conference, Montréal, Canada: “Diagnosis and

treatment of hypercholesterolemia and dyslipoproteinemias” - Dec 1996 • Centre de Recherche sur les Maladies Lipidiques, Québec, QC: “Cellular cholesterol transport in

familial HDL deficiency” - Dec 1996 1997 • Ottawa Heart Institute Lipoprotein Research Group, Ottawa, Ont: “Familial HDL Deficiency: defect in

intracellular cholesterol transport” - Feb 1997 • CME, Mt-Tremblant, QC: "Treatment of lipoprotein disorders in CAD patients" - Mar 1997 • American College of Cardiology Panel, Anaheim, CA: “Homocysteine as an atherosclerosis risk factor”

- Mar 1997 • Centre Hospitalier de l’Université de Montréal Cardiology Conference, Montréal, QC: “The treatment of

coronary artery disease” - Mar 1997 • Merck Advisory Board, Lisbon, Portugal: “Homocysteine and Cardiovascular Diseases” - May 1997 • Association des cardiologues du Quebec, Lyons, France: “Treatment of chronic CAD” - May 1997 • International Conference on Preventive Cardiology. Chair, Novartis Symposium, Montreal, Canada:

“Lipid lowering therapy in the prevention of coronary artery disease” - June 1997 • International Conference on Preventive Cardiology, Chair, Montréal, Canada: "Homocysteine and

cardiovascular disease" - June 1997 • International Conference on Preventive Cardiology, Montréal, Canada: "Homocysteine and CAD" -

June 1997 • International Conference on Preventive Cardiology. Debate, Montréal, Canada: “Apo B should be

included in clinical decision making” (antagonist) - June 1997 • Montreal Children’s Hospital, Saul Usher Memorial Lecture, Medical grand rounds, Montréal, Canada:

"Molecular Genetics and Premature CAD" - Oct 1997 • XI International symposium on atherosclerosis, Paris, France: "Genetics, Lipoproteins Disorders and

Premature Coronary Artery Disease" - Oct 1997. • Cardiology Conference, Montréal, Canada: "Novel approaches in the treatment of dyslipidemias" - Oct

1997 • AHA meeting, Council on Clinical Cardiology: "How to approach and manage high homocysteine

concentrations" - Nov 1997 • CME. Montréal, Canada: “Genetic Lipoprotein Disorders in Premature CAD” - Nov 1997 • Federation des Omnipracticiens du Quebec, Journées du Département de médecine, Université de

Montréal Annual conference, Montréal, Canada: "Secondary prevention of cardiovascular diseases” - Nov 1997

• Hull-Gatineau Physician Association, Hull, QC: “Secondary prevention of CAD” - Dec 1997 • Tufts University symposium on the recent advances in the dietary and pharmacological prevention of

cardiovascular diseases, Boston, MA: “Familial lipoprotein disorders in CAD” - Dec 1997 1998 • Royal Victoria Hospital, McGill University Medical Grand Rounds, Montréal, QC: “HDL and CAD.

Epidemiology and molecular genetics” - Jan 1998 • Queen’s University Biochemistry Department, Kingston, ON: “Homocysteine: epidemiology to

molecular genetics” - April 1998 • Queen’s University, Kingston General Hospital Medical Grand Rounds,Kingston, ON: “High density

lipoproteins in health and in disease” - April 1998 • Vascular Biology Workshop, American Society of Clinical Investigators; American Federation for Clinical

Research, Biomedicine ’98 symposium, Washington DC - May 1998 • Association des Endocrinologues du Québec: “Homocysteine and Vascular Diseases” - May 1998


11

• Canadian Vascular Biology Working Group-2, Banff, Alberta: “Pathogenesis of homocysteine and coronary artery disease” - May 1998

• Hôpital Charles-Lemoyne, Longueuil QC: “New risk factors and CAD” - June 1998 • Royal Victoria Hospital Cardiology Rounds, Montréal: “HDL deficiency states” - Sept 1998 • Canadian Cardiovascular Society Meeting, Ottawa, ON: “Canadian Guidelines for the Diagnosis and

Treatment of Hypercholesterolemia and Other dyslipidemias” - Oct 1998 • Canadian Cardiovascular Society Meeting, Ottawa, ON: “Treatment of hyperlipidemias in patients with

coronary artery disease” - Oct 1998 • Centre Hospitalier de l’Universite de Montreal (CHUM) Cardiology Rounds: “Genetics of Premature

CAD” - Oct 98 • AHA 1998, American Heart Association 71st Scientific Sessions, Dallas Tx: “Treatment of

hyperhomocysteinemia” - Nov 1998 • International Concensus on Homocysteine: the new risk factor for cardiovascular disease:

“Homocysteine and Cardiovascular Risk”. Nice, France, Nov 1998 and Cleveland, OH, Dec 1998 1999 • Jewish General Hospital Endocrinology Rounds, Montréal: “Lipoprotein Disorders, Diabetes and CAD”

- Jan 1999 • Royal Victoria Hospital Cardiology Rounds, Montréal: “Lipoproteins and CAD” - Feb 1999 • Chair, Symposium on Management of Lipoprotein Disorders (CME) Cancun, Mexico - Feb 1999 • American College of Cardiology Conference at Lake Louise, April 1999

• Homocysteine and CAD • The role of triglycerides and HDL in cardiovascular diseases • Preventive Cardiology: risk stratification

• The Health Outcome and Prevention Evaluation (HOPE) investigators, Toronto: “Rationale for a study of Folate for the prevention of cardiovascular diseases” - April 1999

• Homocysteine and Coronary Artery Disease, Atlanta, GA, USA - May 1999 • International Task Force for the Prevention of Coronary Artery Disease, Paris, France: “Homocysteine

as a risk factor for CAD” - May 1999 • Canadian Federation of Biological Societies, Winnipeg, MA: "Homocysteine and Coronary artery

disease" - June 1999 • International Symposium on Diabetes and Cardiovascular Diseases, Winnipeg, MA: "Diabetes,

Lipoproteins and CAD" - June 1999 • Tenth Annual Gunton Symposium on Cardiovascular Diseases. Robarts Research Institute, London,

Ontario: "Mutations at the ABC1/CERP gene locus novel insight in reverse Cholesterol Transport - Sept 1999

• Clinical Research Institute symposium of Nutrition and cardiovascular diseases, Montréal, QC: “Homocysteine and CAD” - Sept 1999

• National Atherosclerosis Forum, Chicago, Ill: "Familial HDL Deficiency/ Tangier Disease” - Sept 1999 • Montreal Children’s Hospital Research Rounds: “Mutations in the ABC1/CERP gene in Familial HDL

Deficiency/Tangier disease” - Nov 1999 • Sunnybrook Hospital, University of Toronto, Cardiology Grand Rounds, Toronto, ON: “ABC1/CERP

gene mutations in FHD/Tangier disease” - Nov 1999 • Parke-Davis Research Laboratories, Ann Arbor, Michigan: “ABC1/CERP mutations in FHD/Tangier

disease” - Dec 1999 2000 • Oregon Science Health University, Portland, OR: “Homocysteine and cardiovascular diseases” - Feb

2000 • American Society for the Advancement of Science (AAAS) annual meeting, Washington DC: "Genetics

of homocysteine and cognitive function". Public Health and Medicine symposium: New knowledge on homocysteine could change public health policy (organized by Dr. R. Malinow).

• Royal Victoria Hospital, McGill University, Medical Grand Rounds: “The ABC of HDL cholesterol” - March 2000

• American College of Cardiology Annual Meeting, Lake Louise, Alberta: "The genetics of CAD" and "Preventive Cardiology" - March 2000

• Center for Molecular Medicine and Therapeutics, UBC and Xenon Biotechnology: "Regulation of the ABCA1 gene and protein". Vancouver BC, April 2000


12

• Tufts University, Physiology Department Guest Scientist: “Cellular cholesterol efflux and ABCA1 gene defects in HDL Deficiency” (Host: Dr. Irwin Arias) Boston, MA May 2000

• Montreal General Hospital Medical Grand Rounds: “ABCA1 gene defects in FHD/Tangier disease”. May 2000

• Centre Hospitalier de l’Université de Montréal Medical Grand Rounds: “Familial HDL Deficiency and Tangier Disease” . May 2000, Montreal Qc

• Heart and Stroke Foundation of Canada / Lewar Cardiovascular Research Fund: “ABCA1 gene defect in Familial HDL Deficienct” Isadore E. Smith Distinguished Visiting Lecture, Toronto, Ontario. May 2000

• Ste-Justine Hospital Pediatrics Research Rounds: “Deficience familiale en lipoproteines de haute densite”. Montreal, May 2000. Host: Dr. E Levy

• Community Physicians, McGill University Health Center: “Guidelines for the treatment of dyslipidemias”, May 2000, Montreal.

• McGill University, B. Robaire Memorial Lecture in Cardiovascular Diseases: `Genetics of Coronary Artery Disease: ABC1 and HDL Deficiency`. June 2000

• Endo-2000. American Endocrinology Society Meeting, Satellite Symposium. “Homocysteine and Cardiovascular Disease “ . Toronto, June 2000

• Keynote speaker, American Association for Clinical Chemistry (AACC): “Molecular Genetics of Coronary Artery Disease: Genetic Lipoprotein Disorders”. San Francisco, CA. July 2000

• Canadian Diabetes Association Annual Meeting: “Emerging Cardiovascular Risk Factors”. Halifax, NS Oct 2000

• Cardiology Research Rounds: “ABCA1 gene defects and HDL deficiency”; Cardiology rounds: “Molecular Genetics of Coronary Artery Disease: Genetic Lipoprotein Disorders” . St-Michael’s Hospital, Toronto Ont, Dec 2000

2001 • Vascular Physicians and Internists, Quebec: “Guidelines for the treatment of dyslipo-proteinemias” Mt-

Tremblant, Quebec, Jan 2001 • American College of Cardiology Annual Meeting, Lake Louise, Alberta: "High Density Lipoproteins

and CV risk" - March 2001 • American College of Cardiology Annual Meeting, Lake Louise, Alberta: "Novel Risk Factors for CAD" -

March 2001 • Medical grand rounds, Jewish General Hospital: “ABCA1 gene and HDL deficiency”. Montreal, Mar

2001 • Vistas of Innovation in Practice: “The Burden of Heart Disease in Canada”. Puerto-Rico, May 2001 • Association des cardiologues du Quebec: “Novel Risk Factors for CAD” Barcelona, May 2001 • Association des Cardiologues du Quebec: “Canadian Guidelines for the treatment of Dyslipidemias”

Barcelona, May 2001 • Ottawa Heart Institute: “A New look at HDL”. Ottawa, Ont. June 2001 • Medical Grand Rounds:”Hyperlipidemias” St-Mary’s Hospital, Montreal General Hospital, Royal

Victoria Hospital, Montreal. Sept 2001 • The Genetics of CAD. AHA Satellite symposium, Nov 2001, Sponsor: Pfizer • Cardiology Grand Rounds, McGill University Hospital Center: “The Heart Protection Study”. Nov 2001 2002 • Canadian Vascular Biology Group. “Novel Risk Factors for CAD”. Whistler BC, Jan 2002 • Gatineau Cardiologist and Specialists: “Rationale for the treatment of LDL-C in CAD patients”. Hull,

Qc, jan 2002 • Annual Cardiology Conference Lake Louise: ”Novel Risk Factors for CAD”. March 2002 • Annual Cardiology Conference Lake Louise: ”Evidence for intensive treatment of lipoprotein

disorders in CAD”. March 2002 • Future Forum, Lisbon, Portugal. “Cellular cholesterol transport defects and HDL”. April 2002 • Medical Grand Rounds, University of Alberta Hospital. “A Better Cholesterol: The ABC’s of HDL”.

Edmonton, June 2002 • Research Seminar, CIHR Cellular and Molecular Lipoprotein Group, Universtiy of Alberta: “ABCA1

phosphorylation and cellular cholesterol efflux modulation”. June 2002 • Society for the Study of Inborn Errors of Metabolism (SSIEM), Planery Session Lecture: “Molecular

Phenotypes in Lipoprotein Disorders”. Annual Meeting, Dublin, Ireland, Sept 2002


13

• Archibald McCallum Lecture, Department of Biochemistry, McGill University: Role of the ABCA1 transporter in cellular cholesterol homeostasis and HDL.

• Canadian Cardiovascular Congress. “Statins in the Prevention of Cardiovascular Disease” Edmonton, Alberta, Oct 2002

• McGill University Refresher Course in Familial Medicine: Canadian Guidelines for the treatment of dyslipidemias 2003. Montreal, Nov 2002

• Symposium on Lipoproteins and CAD:”ABCA1 and HDL deficiency. Tufts University, Boston MA Dec 2002

2003 • Canadian Atorvastatin Research Roundtable, “ABCA1 and the molecular biology of cellular cholesterol

efflux”. Whistler BC Jan 2002 • Canadian Atorvastatin Research Roundtable, “The MARGAUX Study”. Whistler BC Jan 2002 • Preventive Cardiology Symposium: ”The Canadian Guidelines for the treatment of

hypercholesterolemia. Montebello, Qc. Feb 2003 • Annual Cardiovascular Conference, Lake Louise Mar 2003: “Statins in the prevention of cardiovascular

diseases • Annual Cardiovascular Conference, Lake Louise Mar 2003: “Novel Cardiovascular Risk Factors”. • Cardiology Rounds, Centre Hospitalier de l’universite de Montreal. “Lipoprotein disorders and CAD”

April 2003 • Medical Advisory Board, Merck Frosst Canada: Novel Cardiovascular Risk Factors”. Vancouver BC,

April 2003 • Cardiology Rounds, Hopital St-Luc, Montreal. “Lipoprotein disorders and CAD” June2003 • Annual day in Cardiology, Dalhousie University: Novel cardiovascular risk factors” June 2003 • Clnical Symposium in Cardiology, St Johns, NFL June 2003: Canadian Guidelines • Cardiovascular Research Conference, University of Alberta, Foothills Hospital. “Apo AI – ABCA1

interaction”. Calgary Jun 2003 • Medical Grand Rounds, Royal Victoria Hospital: ” Guidelines for the treatment of hypercholesterolemia

and CAD prevention – 2003”. Montreal, Sept 2003 • Montfort Hospital, Ottawa, Ont. “Guidelines for the treatment of hypercholesterolemia and CAD

prevention” Sept 2003 • Robarts Research Institute Gunton Symposium Keynote Speaker: “Risk Determination and

Prevention of CAD”, London, Ont Oct 2003 • Canadian Diabetic Association. Basic Science Lecture: Apo AI – ABCA1 interactions and the

formation of HDL. CDA meeting, Ottawa, Ont, Oct 2003 • Canadian Lipoprotein Conference Lecture: APO AI – ABCA1 intercations Muskoka, Ont. Oct 2003 • Canadian Cardiovascular Congress : Late breaking trials : Risk Factors. Toronto, Oct 2003 • Canadian Cardiovascular Congress : Canadian Guidelines for CAD prevention. Toronto, Oct 2003 • Medical Grand Rounds, Montreal General Hospital : Guidelines for the management of dyslipidemia

and CAD prevention Canada 2003. Oct 2003 2004 • Cardiology Rounds, Queen Elizabeth II Hospital, Halifax NS. “Guidelines for the management of

dyslipidemia and CAD prevention in Canada”. Jan 2004 • CCS `Train the Trainer` symposium. Canadian Guidelines in Hypercholesterolemia. Cancun, Mexico,

Jan 2004 • Centre hospitalier de l’université de Montréal Medicine Grand rounds: “Guidelines for the management of

dyslipidemia and CAD prevention in Canada”. Jan 2004 • Association des cardiologues du Québec: Annual meeting Jan 2004 • Canadian Heart Research Centre:`Prevention of CAD`. Mt Tremblant, Quebec, Mar 2004 • Annual Cardiovascular Conference, Lake Louise: ”Primary prevention of CAD” Mar 2004 • Annual Cardiovascular Conference, Lake Louise: ”C-Reactive Protein and cardiovascular risk” Mar 2004 • McGill University Preventive Cardiology Symposium: “Guidelines for the management of dyslipidemia

and CAD prevention in Canada”. Apr 2004 • Annual Atlantic Cardiovascular Conference: ”Metabolic syndrome”. Halifax, NS, Apr 2004 • Brian Chandler Lecture, Atlantic Cardiovascular Conference: ”Primary prevention of CAD”.

Halifax, NS, Apr 2004 • Débat des Chefs: Lower is Better. Québec, Qc, Mai 2004


14

• Quebec Heart Institute : ”Prevention of CAD”, Québec City, May 2004. • Greater Toronto Area Clinical Cardiology. Keynote Speaker, Annual Meeting Jun 2004, Muskoka, Ont. • IBC USA Cardiovascular Research and Therapeutics Conference: `HDL, CVD risk and Therapeutic

options`, MIT Mass Jul 2004 • Queen`s University Biochemistry Department : HDL and ABC transporters. Kingston, Ont Oct 2004 • Ottawa Heart Institute: High Density Lipoproteins. Ottawa, Ont Oct 2004. • Canadian Cardiovascular Congress 2004; Calgary, Ab

o 4 symposia on cardiovascular risk and therapy of lipoprotein disorders o Clinical Trials Update: Lipid trials

• AHA Scientific Sessions 2004, New Orleans, Cardiovascular Seminars. Invited presentation in Cholesterol transport: ABCA1

• McGill University Genetic Axis and Human Genetic Seminar: HDL Genetics. Nov 2004 • Centre Universitaire de Sante de l’Estrie. Resident Research Day, Keynote speaker : Clinician

Scientists : a career choice. Sherbrooke, Quebec, Nov 2004 • Canadian Advances in Vascular Biology Symposium: `Cholesterol homeostasis in vascular endothelial

cells`, Whistler, BC. Dec 2004 2005

• McGill University CME-Thursday Evening Lectures: Preventive Cardiology. Montreal, Jan 2005 • Canadian Atorvastatin Research Roundtable: MARGAUX study Banff AB, Jan 2005 • Societé de Maladies Vasculaires du Québec. High Density Lipoproteins, Feb 2005, Montréal • CHUM Hopital Hotel-Dieu de Montreal : HAART treated patients and CAD. Feb 2005 • Annual Cardiovascular Conference, Lake Louise: ”Diets for the prevention of CAD” Mar 2005 • Annual Cardiovascular Conference, Lake Louise: ”Genetics of CAD” Mar 2005 • St Paul’s Hospital, Vancouver, BC: ABCA1 and High Density Lipoproteins • Vancouver General Hospital, Vancouver BC: Genetics of Premature CAD • Surrey General Hospital, vancouver, BC: Canadian Dyslipidemias Guidelines • St-Mary’s Hospital Cardiovascular day.: Prevention of CAD and The Metabolic Syndrome. Waterloo, Ont;

April 2005 • University of California in Los Angeles, department of Human Genetics: Genetics of HDL. Apr 2005 • Hopital Notre-Dame, CHUM, Montreal: CAD Prevention and new lipid guidelines. May 2005 • International Atorvastatin/Amlodipine advisory Board, Pfizer: "Amlodipine and Inflammation –the

MARGAUX Study" NYC, NY May 2005. • Canadian Geriatric Society Satellite Meeting: "Lipoprotein disorders in the elderly" Halifax 06.2005 • Federation of European Biochemical Societies Workshop on Recent Advances in Lipid

Metabolism: "ABC transporters in phospholipid and cholesterol transport". Dijon, France, 06.2005

• Quebec Heart Institute, Sept 2005. "Canadian Cholesterol Guidelines". Québec, Canada • Sherbrooke University, Div. Endocrinology: "Biogenesis of HDL" Oct 2005 • Canadian Cardiovascular Congress Oct 2005, Montreal, Qc

o Cardiology trainees conference, Plenary session: "The Future of Cardiovascular Research" o Debate: Lifestyles vs Medication (polymeal / Polypill o Management of lipoprotein disorders for CAD Precvention o CAD prevention on Canada o Reaching Guidelines: targeting LDL

• Geriatric Medicine Grand Rounds: "Lipoproteins and the elderly" Jewish General Hospital, McGill nov 05 • Invited Speaker, Lipoprotein and Atherosclerosis Research Program Group, University of Birmingham

Alabama, “HDL biogenesis”. Dec 2005 2006 • University of Toronto Hospital Network Endocrinology Rounds: “Genetics and CAD Prevention” Jan 2006 • Inter-Hospital Endocrinology Research Rounds; “HDL Biogenesis” Toronto, Jan 2006 • University of Alberta Cardiology Rounds: “CAD Prevention Guidelines in Canada” Jan 2006 • Centre Hospitalier Universitaire de Montréal: “CAD Prevention Guidelines in Canada” Feb 2006 • Annual Cardiovascular Conference Lake Louise Mar 2006

o Symposium on global cardiovascular risk, Chair o Preventive cardiology


15

o Diagnosis and treatment of dyslipidemias • CME on Canadian Dyslipidemia Guidelines to many hospitals • Robarts Research Institute Gunton Symposium Keynote Speaker: “New insights into reverse

cholesterol transport from studies of ABCA1”, London, Ont Apr 2006 • St-Michael Hospital Cardiology research Rounds: “HDL Biogenesis”. Toronto, April 2006 • St-Michael Hospital Cardiology Grand Rounds Rounds: “CAD Prevention guidelines in Canada”. Apr 2006 • Toronto University Hosp Network: “CAD Prevention guidelines in Canada”. Apr 2006 • Association des Internistes du Québec: « CAD Prevention » May 2006, Montebello, Québec • Resident Research Day Guest Speaker, Cardiology Division, Dalhousie University. “Patients, Cholesterol:

lessons learned”. May 2006, Halifax, NS • Winnipeg Health Science Center: Medical Grand Rounds: “Canadian Recommendations for the diagnosis

and treatment of dyslipidemias and CAD prevention”. Sept 2006 • Winnipeg Health Center Lipoprotein Research group: “HDL and cellular cholesterol homeostasis”. Sept

2006 • Royal Univeristy Hospital, Saskatoon Medical Grand Rounds: “Canadian Recommendations for the

diagnosis and treatment of dyslipidemias and CAD prevention”. Sept 2006 • New Brunswick Cardiovascular Symposium: “Approach to the treatment of the low HDL patient” and • “Biomarkers and non-invasive cardiovascular testing”. St John, New Brunswick, sept 2006 • State-of the-Art Lecture, Canadian Cardiovascular Congress: “HDL from bench to population

health”. Vancouver, BC Oct 2006 • CCC 2006 workshop on Genetics/Biomarkers for CV Conditions. Panel member. Vancouver BC Oct 2006 • Medical Grand Rounds, Jewish General Hospital, Montreal Oct 2006: “HDL State-of-the-Arts”. • Canadian Society of Internal Medicine annual Symposium: “Treatment of Lipoprotein Disorders” Calgary,

Nov 2006 • American Heart Association Scientific Sessions: HTS 51: “How to manage the challenging patient with

dyslipidemia”. Chicago, Nov 2006. 2007 • University of Alberta Biochemistry Dept: “HDL Biogenesis” Edmonton, AB, Jan 2007 • Distinguished Visiting Scientist, University of Louisville, KY: “HDL and CVD”. Feb 2007 • Annual Cardiovascular Conference Lake Louise Mar 2007

o Symposium on global cardiovascular risk (Pfizer), Lipid Guidelines o Genetics in the prediction of CAD o HDL: the next therapeutic target?

• American College of Cardiology Chair, session 91: Great Debates in Lipidology. • Distinguished Visiting Scientist, Columbus Children Hospital, Columbus OH, May 2007 • European Atherosclerosis Society HDL Satellite Symposium: HDL Biogenesis. Helsinki, Fn Jun 2007 • Canadian Vascular Biology working group Symposium: “HDL Treatments: lessons from pharmacologic

interventions”. Vancouver BC Aug 2007 • Distinguished Speaker, University of British Columbia: HDL: marker of Health of therapeutic target?”

Vancouver, Sept 2007 • Canadian Cardiovascular Congress 2007. Symposia on:

o Trainee day: Translational Research DNA to prediction; o Merck Annual Debate Lipid Mgt LDL not reached; o How to Best Estimate Cardiovascular Risk in Primary Prevention; o Impact of lipid Rx on CV risk reduction: New agents; o Societal changes to CV risk reduction

• CSATVB President’s Symposium: “HDL Genetics” Quebec city Oct 2007 • Fourth International Endocrinology Symposium, Toronto: “HDL and CVD”. Nov 2007 • Galaxy Symposium, Astra-Zeneca State of the Art Lecture. “The Yin and Yang of HDL” Nov 2007, New

York, NY • McGill University Refresher Course in Medicine: “Cardiometabolic Risk”. Montreal, Nov 2007 • Hamilton General Hospital, McMaster University. Cardiology Grand Rounds: “HDL and CVD” Dec 2007 2008 • University of Alberta Dr. Eldon Smith Annual Lecture, University of Calgary, Feb 2008


16

• Canadian Rheumatology Association: Cardiovascular Risk Evaluation. Mar 2008, Mt. Tremblant, Qc • Abitibi-Teminsgamingue Region (rouyn-Noranga, Amos, Val d’Or, La Sarre). Preventive Cardiology and

McGill RUIS. Mar 2008 • Annual Cardiovascular Conference, Lake Louise. Ronie Campbell Memorial Lecture: Statins at 21. Lake

Louise, Mar 2008 • Annual Cardiovascular Conference, Lake Louise. Alcohol and heart disease. Lake Louise, Mar 2008 • Keynote Speaker, Southlake Hospital Annual Cardiology Symposium: The Yin and Yang of HDL and

Cardiometabolic risk. Toronto, Ont, Maril 2008 • SQLNM (Quebec Lipidol. Soc) Keynote Speaker, Annual Meeting. Montreal, May 2008 • Assoc. Medecins Omnipraticiens de l’Estrie: CVD Prevention, May 2008 • Keynote Speaker, Winsconsin Lipid Club : « HDL and Cardiovascular Disease » Milwaukee May 2008 • Gordon Research Conference on Lipoprotein Metabolism 2008 invited oral presentation: “RVX208

increases apo AI and HDL”. June 2008 • IX World Conference on Clinical Pharmacology and Therapeutics. Planery Lecture: “New Therapies for

Dyslipidemia”. Quebec City, July 2008 • European Society of Cardiology, Invited Speaker: “Genetics of HDL” Session 1665 Aug 2008, Munich GE • Robarts Research Institute Gunton Symposium Keynote Speaker: “New Therapies for HDL”, London,

Ont Sept 2008 • Trillium Medical Center, Toronto, Ont: Statins: Impact on CVD Prevention. Sept 2008 • Canadian Dianbetes Association: Statins and the metabolic syndrome. Montreal, Oct 2008 • International SEAS (Simvastatin+ezetimibe in Aortic Stenosis) Study. LDL and Atherosclerosis. Frankfurt,

Oct 2008 • CCC 2008 Expert Opinion Symposium on Cardiovascula Risk. Debate on LDL-C targets in CVD. Oct 2008,

Toronto • Astra-Zeneca symposium. JUPITER study, Montreal, Nov 2008 • MUHC Medical Grand rounds: “Biomarkers of Inflammation and CVD” Montreal, Nov 2008 • Tan Tok Seng Hospital, Singapore. Grand Rounds “Biomarkers in atherosclerosis” Dec 2008 • Singapore General Hospital, Singapore: Cardiology Rounds: “Jupiter study” Dec 2008 • Yousei University Hospital, Seoul, Korea Cardiology Rounds: “Biomarkers in atherosclerosis” Dec 2008 • Korea University Guro Hospital, Seoul: “Biomarkers in atherosclerosis” Dec 2008 • Catholic University Hospital, Seoul, Korea: “Biomarkers in atherosclerosis” Dec 2008 • Sungkyunkwan University Samsung Hospital, Seoul, Korea: “Jupiter study” Dec 2008 • Cheng Hsin Rehabilitation Medical Center, Taipei, Taiwan: “JUPITER Study” Dec 2008 • Chang Gung Memorial Hospital-Keelung, Keelung, Taiwan. “JUPITER Study” Dec 2008 • Changua Christian Hospital, Taiwan:”Screening and treatment of atherosclerosis” Dec 2008 • Taichung Veterans General Hospital, Taiwan. ”Screening and treatment of atherosclerosis” Dec 2008 • Chang Gung Memorial Hospital-Linkou, Taiwan. ”Screening and treatment of atherosclerosis” Dec 2008 • CME. Singapore, Korea, Taiwan. Dec 2008 ”JUPITER Study” Dec 2008 • CME. Singapore, Korea, Taiwan. Dec 2008 ”Screening and treatment of atherosclerosis” Dec 2008 2009 • Cardiology Rounds; Endocrinology Rounds, CHUM, Montreal. “Biomarkers of Cardiovascular Risk”. Jan

2009 • Cardiology Rounds, Nephrology Rounds, Quebec City, Trois-Rivieres, “JUPITER Study” Jan 2009 • Mazenkowski Heart Institute Guest Lecture: “Biomarkers of Cardiovascular Risk”. Edmonton,Alberta,

Feb 2009 • Annual Cardiovascular Conference, Lake Louise. “Can Lipid Guidelines 2009”. Lake Louise, Mar 2009 • Cardiovascular Research Rounds: ““Biomarkers of Cardiovascular Risk”. Sherbrooke University Mar 09 • Invited Lectures Shanghai, Hangzhou, Nanjing, Beijing, PR China. Biomarkers and Cardiovascular risk:

the JUPITER study. March 2009 • Invited Lectures Ho Chi Minh City, Ha Noi, Vietnam. Biomarkers and Cardiovascular risk: the JUPITER

study. April 2009 • Cardiology Grand Rounds, Dartmouth-Hitchkock Medical center. Biomarkers of CAD Risk. NH, Apr 2009 • Université de Montréal Journées de pharmacologie. Biomarqueurs de risque cardiovasculaire. May 2009 • CME. “The JUPITER Study” Buenos Aires, Argentina, May 2009


17

• Invited Speaker, XXVII Congreso National de Cardiologia Federation Argentina de Cardiologia “Biomarkers (hsCRP) and Cardiovascular risk. Buenos Aires, Argentina, May 2009

• Symposium, The JUPITER Study, XXVII Congreso National de Cardiologia Federation Argentina de Cardiologia “Biomarkers (hsCRP) and Cardiovascular risk”.. Buenos Aires, Argentina, May 2009

• International Symposium on Atherosclerosis. “Canadian Guidelines treatment of Dyslipidemias and prevention of CVD” Invited presentation, Boston, MA Jun 2009

• Interventional Cardiology Symposium: Biomarkers of Atheroscelrosis. Montreal, Jun 2009 • Medical and Cardiology Grand Rounds “Biomarkers (hsCRP) and Cardiovascular risk”. St- Boniface

Hospital, Winnipeg, Jun 2009 • Canadian Vascular Biology Symposium. “CRP Marker/target of therapy”. Vancouver, BC Aug 2009 • CCS symposium: “Jupiter and Canadian lipid guidelines” Vancouver sept 2009 • Ass. Medecine Omnipracticiens de Quebec. Lipid Guidelines, Quebec City Oct 2009 • Novo Nordisk Symposium: Suggogate end-points for atherosclerosis. Copenhagen, Denmark, Oct 2009 • Canadian Cardiovascular Congress 2009 Edmonton

o CSATVB Symposium: HDL Genetics o Beyond 2000 symposium: Canadian Cholesterol Guidelines o Community Cardiology Symposium: the JUPITER Study updates

• J. Hogg i-Capture Research center, St-Paul’s Hospital, UBC Vancouver: Genetics of HDL, Nov 09 • 23rd, Family Physicians clinical updates, Edmonton, Ab. Nov 2009 • CME Rounds on Canadian Cholesterol guidelines (many) 2010 • Societé des Sciences Vasculaires du Québec Jan 2010. Canadian Cholesterol Guidelines • Societé Québecoise d’hypertension artérielle Annaul Meeting, Québec City, Jan 2010 • Annual Cardiovascular Conference, Lake Louise. “Residual Cardiovascular rrisk”. Lake Louise, Mar 2010 • American Heart Association ATVB Conference: “Biomarkers of HDL Function”. San Francisco Apr 2010 • AHA ATVB 2010. San Francisco. Meet the Professor Mentorship luncheon. • First Canadian Summit of surgery for type 2 diabetes: :Diabetes and CVD”. Montreal, May 2010 • I nternational Atherosclerosis Society HDL Workshop: HDL is a better target than LDL. Vancouver May 2010 • AMGEN Corp. “HDL as a Therapeutic Target”. Los Angeles Jun 2010 • New Brunswick Cardiovascular Symposium: “Residual Cardiovascular Risk”. Sept. 2010 • Keynote Speaker, Fraser Health CV Symposiums, Vancouver, Sept 2010; Nov 2010 • Merck US. “HDL Function” Advisory meeting. Rahway, NJ Sept 2010 • CCC 2010 Montreal Oct 2010. Chair, CSATVB trainee's session • CCC 2010 Montreal Oct 2010 Co-Chair Workshop on "Residual CV Risk: HDL as a potential target. • CCC 2010 Montreal Oct 2010 Chair: Symposium on Phytosterols and CV risk • Cardiovascular disease prevention in the HIV patient. Montreal, QC Nov 2010

2011 • Endocrinology Rounds, MUHC “HDL as a treatment Target” Jan 2011 • Dubai Hospital, Dubai UEA; Sheik Kaflia Medical City, Abu Dhabi, Al Noor Hospital, Ai Ain, United Arab

Emirates: “Primary and secondary Prevention of CAD”. Mar 2011 • Doha Medical Center, Qatar; KOC Hospital, Kuwait: “New Paradigm in Cardiovascular Prevention” Mar

2011 • IXth Gulf Heart Association, Muscat, Oman.:”Treatment of Lipoprotein Disorders” (meeting postponed

because of regional political instability) • Annual Cardiovascular Conference, Lake Louise. “Biomarkers of Cardiovascular rrisk”; “Novel lipid

Therapies”, Update on Canadian Lipid Guidelines”. Lake Louise, Mar 2011 • Taiwan Society of Cardiology (TSOC) Symposium Taipei, Taiwan: Biomarkers of Cardiovascular Risk.

May 2011 • Taipei National University Hospital, Chang-Hua Christian Hospital, Yun-Lin National Taiwan

University Hospital, Taiwan.: “Biomarkers of Cardiovascular risk: Lessons from JUPITER. Taiwan, May 2011

• Taipei, Tanchung, Kaoshiung, Taiwan. Conferences to General Practitioners on Biomarkers of Cardiovascular Risk.

• Hoffman- La Roche Pharma. Biogenesis and Genetics of HDL. Basel, Switzerland, May 2011


18

• 21st Cardiovascular Symposium. St. John NB :Biomarkers of Cardiovascular Risk”. Sept 2011 • AMGEN US. PCSK9 levels in JUPITER. Atlanta, GA Oct 2011 • Canadian Cardiovascular Congress 2011, Vancouver BC

o Year in Review: “CRP, Inflammation and CVD” o Debate: “HDL Should be a primary therapeutic target” o Canadian Atherosclerosis Study Group: “HDL and inflammation”

• American college of Physicians / Rocky Mountain Internal Medicne Conference: “Update on Lipids” Banff, Ab, Nov 2011

2012 • Nephrology Rounds Jewish General Hospital,and McGill University Health Centre Mar 2012 • Annual Cardiovascular Conference, Rockies. Novel Approaches to Lipid drugs and “Late Breaking Clinical

trials” Banff, Qb Mar 2012

Academic Activities / Conferences and Symposia (Organizer) • Cardiology conferences, Hôpital Hôtel-Dieu de Montréal; 1991, 92, 93, 94, 95, 96 • Preceptorship, Pfizer Pharmaceutical Group, Hôpital Hôtel-Dieu de Montréal; May 92, 93, 94 • Medical Grand Rounds, Hôpital Hôtel Dieu de Montréal, Cardiology. 91, 92, 93, 94, 95, 96 • Canadian Cardiovascular Society Workshop; Oct 1993 • Symposium on: "Lipoproteins, Coagulation Factors and Diabetes: Major Risk Factors for Coronary

Artery Disease", Co-Chairman; Boca Raton, Florida; Nov 1993 • National Organizing Commitee, Xth International Atherosclerosis Society Symposium, 1994 • Abstract Grader, Xth International Atherosclerosis Society Symposium, Montréal, Canada, 1994 • Co-Chair, symposium on "Global risk assessment for CAD: from epidemiology to medical practice". Xth

International Atherosclerosis Society Symposium, Montréal, Canada, 1994 • Preceptorship, Parke-Davis and Pfizer pharmaceutical group. “Diagnosis and treatment of

dyslipidemias”. Montréal; Nov 1996 • Chair, Symposium on Management of Lipoprotein Disorders (CME), Cancun, Mexico; Feb 1999 • Chair and Organizer, Symposium on Nutrition and Cardiovascular Diseases, IRCM, Sept 1999 • President, Canadian Lipoprotein Conference, 1999; Organizer, CLC meeting, Mt-Tremblant, Québec,

Canada • Chair, Canadian Atorvastatin Research Roundtable, Jan 2000, New York, NY • Chair, symposium on Vistas of Innovation in Practice. Puerto-Rico, May 2001 • Chair, Innovations in Clinical Practice, AHA 2001, Sponsor: AstraZeneca satellite symposium • Chair, Lipitor Steering committee, Anaheim Ca, Nov 2001 • Chair, Symposium on the “New Landscape on Dyslipidemias”, San Diego, May 2002 AstraZeneca • Chair, Canadian Atorvastatin Research Roundtable, Jan 2003, Whistler, BC • Chair, Preventive Cardiology Symposium, McGill University. Montebello Qc, Feb 2003 • Chair, Innovations in Dyslipidemias. Sponsored by Astra-Zeneca; Chicago, March 2003 • Chair, Meet the Experts Session, Canadian Cardiovascular Congress, Prevention Guidelines. Oct

2003, Toronto • McGill University Hospital Center Research Institute Cardiovascular Disease research Axis research

day, Jan 2004 • Chair, Preventive Cardiology Symposium, McGill University. Montreal, Qc, Apr 2004 • Canadian Cardiovascular Congress Scientific Program Chair, 2004 • Canadian Cardiovascular Congress Scientific Program Chair, 2005 • Chair, Canadian Atorvastatin Research Roundtable, Jan 2005, Banff, AB • McGill University Cardiovascular Research / Critical Care Research Axis Research Day 2004, 05,

06, 07, 08, 09, 10 • Co-Chair McGill University faculty of Medicine symposium (25th class reunion) Sept 2005 • Chair, Louis and Arthur Lucian Award Committee, McGill University 2006- • Global Cardiovascular Risk. ACC Lake Louise Symposium, Chair. (Pfizer) March 2006 • Chair and organizer, Canadian Cardiovascular Congress 2006 Workshop on Lipid Guidelines. • ACC Lake Louise Symposium 2007 on global cardiovascular risk (Pfizer), Chair


19

• ACC Lake Louise Symposium 2007 on the vulnerable plaque (Astra-Zeneca), Chair • Chair and organizer, Astra-Zeneca symposium on “Insights into the management of cardiovascular risk in

the vulnerable patient. CCC 2007, Quebec • Co-Chair, Meet-the-experts session on cardiovascular risk stratification, CCC 2007, Quebec • Chair, CCC 2007 session: Lipid lowering therapies • Chair, AHA 2007 session: ATVB –Lipid and Lipoproteins IV • Chair, ACC Lake Louise Merck Frosst Satellite Symposium March 2008 • Annual Cardiovascular Conference, Lake Louise Co-Chair, 2009, 10, 11 • Chair, CCC 2008 Expert Opinion Symposium on Cardiovascula Risk. Oct 2008, Toronto • Canadian Cardiovascular Society Congress 2009. Workshop on Canadian Cholesterol Guidelines • Canadian Cardiovascular HArmonization of National Guidelines Endeavour (C-CHANGE) member 2009- • ACC Lake Louise Cardiology Residents Research Competition, organizer, 2010 • Chair, AMGEN advisory board, Monreal Feb 2012 • Annual Cardiovascular Conference, Rockies (Banff, AB) 2012 Co-Chair

Advisory Boards: • Pfizer Canada. Lipitor advisory board 2000-2010 • Astra-Zeneca. International and National advisory board 2000- • Merck Frosst – Schering Plough advisory board 2002- • Liponex Scientific Advisory Board 2002-05 • Resverlogix Scientific Advisory Board 2003-09 • Xenon genetics Scientific Advisory Board 2000-2002 • Canadian Skin Sterol Scientific Advisory Board 2002-3 • Centocor (Johnson & Johnson) Scientific Advisory Board 2003 • Bayer Advisory Board, 2004 • Servier Advisory board -2004, 05 • Novartis, Boston, 2005 • Glaxo-Smith-Kline 2006-07 • Merck Sharpe Dohme 2007- International advisory board • Genzyme (Wellchol) Canadian Ad board 2007 • Solvay 2009- • Danone, France 2010- • MicroPharma, Montreal 2010- • Ascati Pharma Scientific Advisory Board 2010- • Merck International 2010- • AMGEN US advisory Board 2011- • Neutrasource. LP-PLA2 biomarker of CV risk 2011- OTHER CONTRIBUTIONS Fund Administrator

• McGill University Cardiology Endowed funds 2000-2010 (total 1,600,000 $ CAD) • McGill University George Fraser Endowment Fund (Fund initiator, 2003) • McGill University Lucian Award Fund 2007-

Infrastructure

• Oversaw the refurbishment of the Cardiology Division infrastructure at the McGill University Health Centre (MUHC) 2000-2010, $34,000,000

• Creation of the Center for Innovative Medicine (CIM), as part of the Research Institute of the MUHC (2008-present), CFI award ($250,000,000 for the construction of both basic and clinical research centers);

• Fond de Recherche du Quebec – Sante: Infrastructure fund $1,057,000 (2010-12) to set-up the CIM manpower.

Foundation, Royal Victoria Hospital.


20

• Private donation, $1,000,000 for the CIM (2011) • Donation from the Armand Bombardier Foundation ($4,000,000) for the purchase of a PET/MRI for the CIM (2011) • Donation from the Lorne Trottier Family for the CIM and Centre for Translational Biology ($10,000,000), 2011-12

Editorial Board Canadian Journal of Cardiology 1999-2009 Journal Reviewer

• Journal of Clinical Investigations • Circulation • Arteriosclerosis Thrombosis and Vascular Biology 3-4 papers/year • Canadian Journal of Cardiology • American Journal of Cardiology • Journal of the American Medical Association • Clinical and Investigative Medicine • Metabolism • Journal of the American College of Cardiology • Atherosclerosis • Hypertension • American Heart Journal • Clinical Genetics • Human Genetics • The Lancet 2000, 10, 11 (3) • American Journal of Pathology 2000- • Abstract reviewer, American Heart Association 1998, 99, 2000, 01, 02, 03, 04, 05, 06, 07, 08 • Abstract reviewer, Canadian Cardiovascular Society 1999, 2000, 01, 02, 03 • Abstract reviewer, Asian-Pacific AHA Cardiology meeting 2001-02 • Journal of Biological Chemistry 2002, • American Journal of Physiology 2003- • European Journal of Cardiology 2004- • J Med Gen 2006- • Biochemistry 2006- • Biochemistry and Cell Biology-2007 • Journal of Lipid Research 2000 (3-5 / year) • BBA Lipids 2008- • Abstract reviewer, American Heart Association ATVB Annual Meeting 2010 • Abstract reviewer, International Atherosclerosis Society meeting, 2012 Grant Reviewer • Medical Research Council of Canada, external reviewer (1991-) • Fonds de la recherche en santé du Québec (1991-) • Heart and Stroke Foundation of Canada External Reviewer (1992-) • Canadian Diabetes Association ad hoc reviewer (1993, 2000) • Kidney Foundation of Canada ad hoc reviewer (1993) • Grant Agency of the Czech Republic ad hoc reviewer (1993-4) • Alberta Heritage Foundation ad hoc reviewer (1996) • The Dairy Board of Canada ad hoc reviewer (1997) • Internal Review Committee, Fonds de la recherche en santé du Québec, Scientist Awards Junior II

1999-2001 • Internal Review Committee VI, Heart and Stroke Foundation of Canada, 1999-2000 • Canadian Institutes of Health Research (CIHR) Internal Reviewer, CV System B 2000, 01, 02, 03 • Fonds de la recherche en santé du Québec, President, Junior I committee, 2001, 02, 03 • Canadian Fund for Innovation. FRSQ Reviewer 2003


21

• Diabetes UK ad hoc reviewer, 2004, 2006 • CIHR external reviewer ad-hoc 2004- • NIH Project Program Grant ad-hoc internal reviewer 2006 • Fonds de la recherche en santé du Québec, Chercheurs Nationaux Program, 2008, 09, 10 • CIHR Clinical Trials « D » Committee Committee (CTD) Member 2011- • Universite of Otago, New Zeland. Ad-hoc promotion committee external expert 2011 • Wellcome-Trust Funding agency, UK. Ad-hoc review committee external expert 2011

Professional Associations 1981- Québec Medical Association Member 1981- Corporation professionnelle des médecins du Québec Member 1981- Canadian Medical Association Member 1981-85 American College of Physicians Associate 1985- Royal College of Physicians and Surgeons of Canada Fellow 1988- Association des cardiologues du Québec Member 1988- Canadian Cardiovascular Society (CCS) Member 1988-00 American College of Cardiology (ACC) Fellow 1989- American Heart Association (Arteriosclerosis) (AHA) Fellow 1992-99 Canadian Atherosclerosis Society (CAS) Member 1995-99 Canadian Society of Clinical Investigations (CSCI) Member 2000- Canadian Soc. Atheroscler. Thromb. Vasc Biol Member 2007- American Society for Biochemistry and Molecular Biology Member

Other • Québec Heart Foundation. Lipid Disorders in Coronary Disease (1991) • Canadian Cardiovascular Society. Post-myocardial Infarction Consensus Conference (Secondary

Panel) (1993) • Québec Government Pharmacology Council. Expert panel on Hyperlipidemia Management (1994). • Québec Heart Foundation: Cholestaction (Vice president, 1994-) • Santé Québec, Cardiovascular Disease. Ministère de la Santé et des services sociaux du Québec

(1994) • Canadian Cardiovascular Society, Post-myocardial Infarction Consensus Conference (1994) • Health Canada. Working group on diagnosis and treatment of hypercholesterolemia and other

dyslipoproteinemias (1994-99) • Genetics Advisory Committee. Conseil d’évaluation des technologies de la santé, Gouvernement du

Québec 1996-97 • International Advisory Panel, FIELD study 1997- • Berkeley Heart Lab. Scientific Advisory Board. 1997-98 • Canadian Society of Clinical Investigations (CSCI) Councilor, 1997-2000 • Scientific Committee, Quebec Heart Foundation 1998- • Cardiac End-Point Committee, VISP (Vitamins in Ischemic Strokes Prevention) Trial 1998-2003 • Homocysteine and Cardiovascular Disease International Consensus Conference, 1998-9 • Canadian Cardiovascular Consensus Conference on the Prevention of Cardiovascular Diseases 1998-

2000 • Heart and Stroke Foundation of Canada Consensus statement on homocysteine and cardiovascular

diseases. 2000; • Health Canada. Canadian Guidelines for the Management of Dyslididemias and CAD Prevention in

Canada. 2002-3 • Head, Réseau Universitaire Intégré de Santé de McGill RUIS) sub committee on cardiovascular

sciences, chair (2005-10) • President, Affaires Santé, Fondation des Maladies du Cœur du Québec (HSFQ) 2006 • Royal victoria Hospital Foundation Board member 2006- • Member, Canadian Heart Health Strategy and Action Plan (CHHS-AP), Theme 3: Preventing, detecting

and controlling major risk factors. Canadian Federal Initiative. 2007-


22

• External reviewer, University of British Columbia Division of Cardiology (Requested by the University) Oct 2008

• External Reviewer, University of Ottawa Academic promotion Committee (2009) • International Atherosclerosis society (IAS) Excecutive Board Mamber 2009- • Promotion committee External reviewer Kuwait University (2009) • Promotion committee External reviewer Universite de Sherbrooke (2009)


23

RESEARCH Research Activities My main research interest is to better understand genetic and metabolic factors in premature coronary artery disease in man. A major focus is on the study of genetic factors that modulate plasma lipoproteins and apolipoprotein levels. I have undertaken four broad areas of research in the past 17 years:

a). Genetics of low HDL-cholesterol states. b). Biogenesis of HDL particles by studying molecular cellular physiology of cholesterol transport c). Setting up a Cardiology/Prevention clinic in which metabolic and genetic factors leading to coronary

artery disease are studied. This clinic provides a service to patients with premature CAD. d). Study of homocysteine as a risk factor for CAD and the genetics of elevated homocysteine.

G2. Salary Support Date Yrs Agency Title Amount1991 2 FRSQ Familial Combined Hyperlipidemia $20,0001992 5 MRC Scholarship. Familial Combined Hyperlipidemia $120,0001992 3 HSFC Scholarship. Familial Combined Hyperlipidemia declined1992 3 FRSQ Scholarship. Familial Combined Hyperlipidemia declined1997 4 FRSQ Familial HDL Deficiency Salary Award/Senior I Level $30,0002000 4 FRSQ Chercheurs Nationaux 2000 5 McGill McGill-Novartis Chair in Medicine (Cardiovascular Diseases) 2001 5 CIHR CIHR-Industry Chair in Medicine 2006 5 McGill McGill / Novartis Chair in Medicine FRSQ: Fonds de la recherche en santé du Québec MRC: Medical Research Council of Canada HSFC: Heart and Stroke Foundation of Canada CIHR: Canadian Institutes of Health Research


24

Grant Support (Past) Date Yrs Agency Title Role Amount 1991 1 Industry Secondary prevention Clinic Princip. Invest. $10,0001991 2 FRSQ Familial Combined Hyperlipidemia Princip. Invest. $10,0001992 1 Industry Secondary Prevention Clinic Princip. Invest. $35,0001992 3 MRC Familial Combined Hyperlipidemia Princip. Invest. $120,0001992 3 HSFC Molecular Genetics of Hyperhomocysteine ‡ Co-princip. Inv $30,0001993 1 IRCM Institutional Funds Princip. Invest $10,0001993 1 Industry Secondary Prevention Clinic Princip. Invest $38,4501993 1 MHI Familial Combined Hyperlipidemia Princip. Invest $10,0001994 3 HSFC LDL-R Gene Regulation in FH Princip. Invest $30,0001994 1 Industry Secondary Prevention Clinic Princip. Invest $27,5001995 3 MRC MT 12884 Cholesterol Efflux in HDL Deficiency Princip. Invest $138,0001995 1 IRCM Institutional Funds Princip. Invest $20,0001995 1 Industry Secondary Prevention Clinic Princip. Invest $30,0001996 1 Industry Secondary Prevention Clinic Princip. Invest $25,0001996 3 HSFC Cholesterol Efflux in HDL Deficiency Princip. Invest $45,0001996 1 Merck USA Novel LDL-R Mutation Princip. Invest US$25,0001997 1 Industry Secondary Prevention Clinic Princip. Invest $30,0001997 4 NIH Genetic Risk Factors for Hyperhomocysteine † Collaborator $14,0001998 3 MRC MT 15042 Cholesterol Efflux in HDL Deficiency Princip. Invest $216,0001998 2 MRC/PMAC 15248 Homocysteine in Diabetics (DAIS clinical) Princip. Invest $41,5001998 3 MOD Homocysteine in Premature Births § Collaborator $45,0001998 2 Xenon BioResearch HDL Deficiency States Collaborator $150,0001999 7 MRC (clinical trials)* HOPE-TOO Homocysteine and CAD Co-Princip. Inv $7,000,0002000 2 Xenon BioResearch ABC1 Gene Regulation Princip. Invest. $100,0002000 2000

3 3

Parke-Davis USA/ MRC- DOP 40845

CERP and Cholesterol Efflux Princip. Invest. Princip. Invest.

$116,000$159,000

2000 3 HSFC Cellular Cholesterol Efflux Princip. Invest. $36,0002001 5 CIHR MOP 15042 ABCA1 and the molecular physiology of

cellular cholesterol efflux Princip. Invest $565,835

2001 3 MOD (PERI 20-FY04-38).

Homocysteine in Premature Births § Collaborator $45,000

2002 3 CIHR ¶ Inherited thrombophilia and endothelial dysfunction in pre-eclampsia

Co-Applicant $48,505

2002 4 NIH (renewal) Genetic Risk Factors for Hyperhomocysteine † Collaborator $42,0002002-3 CFI #3154 Genetics of Cardiovascular Diseases Co-Princip. Inv $415,7762003 CFI #5171 Cardiovascular Studies Network Co-Princip. Inv $333,0002003 3 CIHR MOP 62834 Genetics of HDL Princip. Invest $532,8062003 3 HSFC ABCA1, Lp (E) and (LRP) Princip. Invest $51,0002003 3 HSFC SMPD-1 and HDL-C Co-Applicant $51,0002003 3 CIHR Training Grant/Lipoprotein Course (D Vance, Pl) Co-Applicant $81,0002005 3 CIHR TEAM Study, L. Lalonde PI Collaborator $478,6222006 3 HSFC Non ABCA1 Chol efflux defect Princip. Invest

Co-Applicants M. Marcil S. Rashid

$59,000

2006 3 Pfizer CV Grant Fine mapping of HDL-C Princip. Invest Co-Applicants:

J. Engert P. Pajukanta

M. Marcil

$330,000

2006 3 CIHR MOP 62834

Genetics of HDL Princip. Invest Co-Applicants:


R. Hegele

$530,000


25

2007 2 Can Foundation

for Kidney Diseases

ABCG1 in Vascular endothelial cells Co-Applicant PI: F. Madore

$100,000

2007-8 1 Resverlogix Biotech company. Evaluation of HDL compound Princip. Invest

$106,000

2006 5 CIHR Mass Spectroscopy Facility McGill Collaborator PI: O Mamer

$593,358

2007 2 CIHR Cardiac outcomes in the metabolic syndrome Co-Applicant PI: M. Eisenberg

K. Filion L. Pilote P. Poirier S. Rinfret E. Schifrin

$112,816

2010 1 CIHR MCR 213254

ACC Lake Louise 2010 Annual Cardiovascular conference

Princip Appl Co Appl: R. Welsh

$10,000

2006 5 CIHR MOP 15042

HDL Biogenesis Objectives: Understand the molecular mechanisms of HDL formation via the ABCA1 transporter; study of the quaternary arrangement of ABCA1 and lipidation site.

Princip. Invest Co-Applicants:

M. Marcil L. Krimbou

$480,000

2009 2 Merck Canada HDL Proteomics Objectives: characterize the HDL proteome in acute inflammatory state associated with acute coronary syndromes

Genest J

$56,000

2010 1 RI-MUHC Equipment Grant (NO Analyzer) Objectives: set-up biomarkers of HDL function

Genest $36,400

2010 1 CIHR MCR 213254

ACC Lake Louise 2010 conference Annual Cardiovascular

Princip Appl Co Appl: R. Welsh

$10,000

On Going Grants (Bold: Genest is PI)

Date

Yrs Agency Title

Role Amount

2007 5 CIHR CTP 82946

CIHR Team in Cardiovascular Disorders Objectives: Human (genetic and biochemical) studies of PCSK9 in man

Co-Applicant PI. N. Seidah

$130,000$4,578,345

2008 5 CFI Research Institute of the MUHC Theme 1: Center for Innovative Medicine (CIM). Large Scale Endeavor (LSIE) to build the Research Institutes of the MUHC

TEAM 1 Leader: J. Genest

PI: V. Papadopoulos

$250,000,000($250M)

2008 3 HSFC Genetics of HDL Objectives: Identify novel genes related to high-density lipoproteins (HDL) by the study of families with HDL deficiency



$102,000

2009 4 CIHR MOP 97752

Genetics of HDL Objectives: Characterize the role of a novel HDL-associated gene, WWOX, identified by our group



C. Croce R. Aqeilan

$472,000

2010 3 CIHR MOP

SMOKELESS trial Collaborator on biomarkers of vascular function

Co-Appliquant PI: S. Daskalopoulou

C. Franco

$307,775

2011 2 FRQ-S Subvention aux centres de recherché cliniques

Genest/Papadopoulos $1.110,000

2011 5 CIHR MOP 15042

HDL Biogenesis Molecular mechanisms of apo AI interaction with membrane micro-domains and regulation of HDL biogenesis and function


$625,000

• *Represents total amount of grant • Non peer-reviewed (pharmaceutical or biotech) grants not included CFI: Canadian Fund for Innovation (portion attributed to my research unit/lab) CIHR: Canadian Institutes of Health Research FRSQ: Fonds de la recherche en santé du Québec HSFC: Heart and Stroke Foundation of Canada NIH: National Institutes of Health, USA BOLD: Grants held as Principal Investigator


27

Clinical Studies • A comparison of Lovastatin and cholestyramine in primary hypercholesterolemia. Principal

Investigator. Merck Frosst Canada 1991-92 ($10,000) • Quality of Life Study of Pravastatin vs. Lovastatin in primary hypercholesterolemia. Principal

Investigator; Montréal Heart Institute. Bristol-Myer-Squibb. 1992-93 ($75,000) • Diabetes Atherosclerosis Intervention Study (D.A.I.S.). Principal Investigator. Fournier Pharma,

France. 1993-present ($500,000/5.5 years) • A comparison of simvastatin alone or with colestipol in the treatment of primary

hypercholesterolemia. Principal Investigator. Upjohn. 1993- 94 ($18,000) • Randomized, placebo-controlled study of micronized fenofibrate on postprandial lipoproteins and

hemostatic factors. Principal Investigator; PI initiated protocol. Fournier Pharma. 1994-97 ($96,000).

• Multicenter, randomized, parallel group, 8-week comparative dose efficacy and safety of

atorvastatin with that of lovastatin, pravastatin, simvastatin and fluvastatin in patients with elevated LDL-cholesterol (CURVES Study). Co-Investigator. 1995-97 present (USD$42,000).

• Open-label treatment protocol for the use of atorvastatin (CI-981) in the treatment of patients with

severe hypercholesterolemia. Compassionate use protocol, Parke-Davis 981-080. Local Investigator 1995-97.

• Women Atorvastatin Treatment of Cholesterol (WATCH). Open-label atorvastatin study in

women. Principal Inverstigator. Treat-to-target primary end-points. (1997-). • IMPACT. A comparative study of micronized fenofibrate and pravastatin in primary

hypercholesterolemia. Protocol FEN 9606, Fournier Pharma. (1997-) • Simva-Atorvastatin. High dose simvastatin versus atorvastatin in patients with

hypercholesterolemia. Merck protocol 140. (1997-) • FACT. Comparative study of micronized fenofibrate (200 vs. 267 ug) in the treatment of

hypercholesterolemia. Fournier Farma protocol FEN-9607. (1997-) • WIZARD study. Azythromycin in patients with CAD and elevated c. Pneumoniae titers. Pfizer.

1998-2000 • TNT study (Treat to New Targets). A multicenter, randomized trial of secondary prevention with

atorvastatin 10 mg vs. 80 mg. Parke-Davis. Principal investigator, IRCM / McGill center. 1998-2004

• CAN-ada study (Canadian Atorvastatin in Diabetics with Atherosclerosis study). Randomized

trial of atorvastatin 10 vs. 80 mg in inschemic coronary syndromes in diabetic subjects. Parke-Davis. 1998-2000

• Randomized, double-blind, parallel group evaluation of cerivastatin 0.8 mg compared with

cerivastatin 0.4 mg and placebo once daily in patients with hypertriglyceridemia. Bayer. 1999-2000

• Randomized trial of the ACAT inhibitor Avasimibe on angina threshold in patients with coronary

artery disease (Phase II). Parke-Davis. 1999-2001 • Randomized phase II trial of CL-1027 in patients with low HDL-C. Canadian site. Pfizer 2000- • PRINCESS Study Study. Terminated by Sponsor (BAYER) 2001


28

• Myocardial revascularization with VGEF Study, Pfizer, Ann Arbor. Michigan 2001 • Modulation of Arterial Reactivity with Amlodipine/Atorvastatin by Ultrasound Examination

(MARGAUX Study). Initiated by myself and co-investigator, Dr. F. Charbonneau, MUHC. Pfizer. 2000-

• JUPITER trial. RDBPC Phase III study of rosuvastatin in the primary prevention of cardiovascular

events in subjects with low levels of LDL-C and elevated hsCRP (n=17,000 subjects). Sponsor: Astra-Zeneca

• ILLUMINATE. Torcetrapib (CETP) inhibitor in subjects with CAD or diabetes. RDBPC phase III

study (n=13,000). Sponsor: Pfizer. Study ended Dec 2006 Publications: • Barter P et al. HDL cholesterol, very low levels of LDL-C and cardiovascular events.

NEJM 2007;357:1301-10 • HDL Treatment study. Investigator initiated. Single site study of treatment of genetic HDL

deficiency. Genest J PI (Am J Cardiol 2008;24:27-31C)

• HDL Proteomics in Acute Coronary Syndromes. Investigator initiated. Single site study of HDL Proteomics in ACS. Genest J PI (Partial funding from MERCK 2009-10) (BBA Lipids 2011)

• SATURN, (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin

Versus AtorvastatiN), is a 104-week, parallel-group, multicentre, double-blind, Phase IIIb intravascular ultrasound (IVUS) imaging study of approximately 1,300 patients at 170 centres worldwide

• AMG 145 A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Subjects With Heterozygous Familial Hypercholesterolemia. 2011-

• REVEAL. Randomized Evaluation of the Effects of Anacetrapib through Lipid-Modification (HPS 3/TIMI 55: REVEAL) Genest is Canadian Lead investigator 2011-

Steering Committees • Women Atorvastatin Treatment of Cholesterol (WATCH) Trial. Dr. Ruth McPherson, Dr. Jacques

Genest (Parke-Davis) 1997-99 • Diabetes Atherosclerosis Intervention Study (DAIS) Dr. George Steiner, Dr. Jacques Genest et

al. (WHO, Fournier) (1993-2000) • Health Outcomes and Prevention Evaluation-2 (HOPE-2) –Folate, vitamins B6 and B12 in the

prevention of cardiovascular diseases. Dr. Eva Lonn, Dr. Salim Yusuf, Dr. Jacques Genest (1999-2005)

• Modulation of Arterial Reactivity Using amlodipine/Atorvastatin by Ultrasound Examination

(MARGAUX) Study. Dr. Francois Charbonneau, Dr. Jacques Genest, PI, study initiator (Pfizer) (2000-2004)

• JUPITER trial (Justification for the use of statins in primary prevention: an Intervention Trial

Evaluating Rosuvastatin). Paul Ridker PI, James Willerson, Peter Libby, Antonio Gotto, Jacques Genest (Astra-Zeneca) 2003-

• JEWEL Study Dr. R. Hobbs (UK), Dr. Jacques Genest (Canada) et al. (Pfizer) 2004-

• Improved Reduction of Outcomes: VYTORIN Efficacy International Trial (IMPROVE-IT): Examining Outcomes in Subjects With Acute Coronary Syndrome:Vytorin (Ezetimibe/Simvastatin)


29

Vs Simvastatin (Study P04103)) PI: Dr. Eugene Brauwnald, Dr. Christopher Cannon. IMPROVE-IT trial 2004- Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM; IMPROVE-IT Investigators. Am Heart J. 2008 Nov;156(5):826-32.

• Lalonde L, Genest J Jr, Blais L, Perreault S, Villeneuve J, Lussier MT, Hudon E, Vanier MC,

Lamarre D. Randomised controlled trial to evaluate an ambulatory integrated primary care management program for patients with dyslipidemia: TEAM Study. Octobre 2005 à octobre 2008. Sponsored by AstraZeneca. 109 941 $; Merck Frosst Canada. 109 941 $; Pfizer Canada Inc. 109 941 $; Total : 329 823 $

• CANTOS. Canakinumab Anti-inflammatory ahtero-Thrombosis Outcomes Study. Dr. Paul Ridker.Peter Libby PI. Novartis funded 2010

• REVEAL. TIMI 55. Heart Protection Study-3. Randomized EValuation of the Effects of Anacetrapib through Lipid modification. Oxford University and TIMI group, Boston


30

PUBLICATIONS [†]: Invited; [*]: Direct supervision; [Grant #]: Granting agency; number

a) Articles in peer-reviewed journals 1 Roussos CS, Fixley M, Genest J, Cosio M, Kelly S, Martin RR, Engel LA. Voluntary Factors

Influencing the Distribution of Inspired Gas. Amer Rev Resp Dis 1977;116:457-467 2 Durand L-G, Genest J Jr, Guardo R. Pharmacological modulation of heart sound transmission in

dogs. Proc. IEEE Frontiers Eng. Comp. Health Care. 1984:450-54 3 Sniderman A, Teng B, Genest J, Cianflone K, Wacholder S, Kwiterovich P Jr. Familial Aggregation

and Early Expression of Hyperapobetalipoproteinemia. Am J Cardiol 1985;55:291-295 4 Genest J Jr, Durand L-G. Relationship of the left ventricular and apical first sounds to the left

ventricular pressure derivative. Medical and Biological Engineering and Computing, 1985;23:95-98 5 Durand L-G, Genest J Jr, Guardo R. Modeling of the Transfer Function of the Heart-Thorax Acoustic

System in Dogs. IEEE Transactions on Biomedical Engineering, Vol. 1985;BME-32(8):592-601 6 Genest J, Sniderman A, Cianflone K, Teng B, Wacholder S, Marcel Y, Kwiterovich P Jr.

Hyperapobetalipoproteinemia: Plasma Lipoprotein Responses to an Oral Fat Load. Arteriosclerosis 1986;6:297-304

7 Kuchel O, Nguyen TB, Larochelle P, Hamet P, Genest J Jr. Episodic Dopamine Discharge in

Paroxysmal Hypertension. Page's Syndrome Revisited. Arch Intern Med 1986;146:1315-1320 8 Schaefer EJ, Rifkin RD, Genest J. Diagnosis and management of lipid disorders. Cardiovasc. Rev.

& Reports 1987;8(11):19-22 9 Fitchett DH, Simkus G, Genest J, Marpole D, Beaudry P. Effect of nitroglycerin on left ventricular

hydraulic load. Canadian J of Cardiol 1988;4(2)72-75 10 Genest J, Corbett HM, McNamara JR, Scheafer MM, Salem DN, Schaefer EJ. Effect of

Hospitalization on High-Density Lipoprotein Cholesterol in Patients Undergoing Elective Coronary Angiography. Am J Cardiol 1988;61:998-1000

11 Genest J Jr, Ordovas JM, Robbins AH, King DC, Frossard PM, Schaefer EJ. Two new apoB gene

polymorphisms:Rs1 and Rs2. Nucleic Acid Res. 1988;16(17):8746 12 Genest J Jr, Ordovas JM, Robbins AH, King DC, Frossard PM, Schaefer EJ. Two new ApoB

polymorphisms: Rs3 and Rs4. Nucleic Acid Res. 1988;16(17):8747 13 Schaefer EJ, McNamara JR, Genest J Jr, Ordovas JM. Clinical Significance of Hypertriglyceridemia.

Sem. Thrombosis and Hemostasis 1988;14(2)143-148 14 Schaefer EJ, McNamara JR, Genest J Jr, Ordovas JM. Genetics and Abnormalities in Metabolism

of Lipoproteins. Clin Chem 1988;34:B9-B12 15 Schaefer EJ, McNamara JR, Genest J Jr, Ordovas JM. Genetic High-Density Lipoprotein

Deficiency. In: "High Density lipoproteins, reverse cholesterol transport, and coronary heart disease", N.E. Miller ed. Exerpta Medica, Elsevier Science Publishers, Amsterdam, 1989.

16 Norman RA. Genest J Jr. Tuberoeruptive Xanthomas: Unusual Presentation of Type V

hyperlipoproteinemia. Cutis 1989;43:169-171 17 Morin Y. MD, Bertrand L, Genest J. Jr MD, Lebrun M. MD, Lussier-Cacan S. Ph. D., Phaneuf D-C.

MD, Théroux P. MD. Lipid Disorders and Coronary Heart Disease. Report from a working group of the Québec Heart Foundation. May, 1989


31

18 Genest J Jr, Ordovas JM, McNamara JR, Robbins AM, Meade T, Cohn SD, Salem DN, Wilson PWF, Masharani U, Frossard PM, Schaefer EJ. DNA polymorphisms of the apolipoprotein B gene in patients with premature coronary artery disease. Atherosclerosis 1990;82:7-17

19 Genest J Jr, McNamara JR, Ordovas JM, Martin-Munley S, Jenner JL, Millar J, Salem DN, Schaefer

EJ. Effect of Elective Hospitalization on Plasma Lipoprotein Cholesterol and Apolipoproteins A-I, B and Lp(a). Am J Cardiol 1990;65:677-679

20 Genest J Jr, McNamara JR, Salem DN, Wilson PWF, Schaefer EJ, Malinow MR. Plasma

Homocyst(e)ine Levels in Men With Premature Coronary Artery Disease. J Am Coll Cardiol 1990;16:1114-1119

21 Genest J Jr. Physicians’ Guide to the Management of Lipoprotein Disorders (book). 1990 STA

Communications, Montréal, Canada (English/French) ISBN 0-919391-14-I 22 Ordovas JM, Civeira F, Genest J, Schaefer EJ. Genetic high density lipoprotein deficiency states.

Biotechnology of Dyslipidemias: Applications in Diagnosis and Control. C. Lenfant (ed.). Raven Press, New York 1990

23 Ordovas JM, Civeira F, Genest J Jr, Craig S, Robbins AH, Meade T, Pocovi M, Frossard PM,

Masharani U, Wilson PWF, Salem DN, Ward RH, Schaefer EJ. Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus: Relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis 1991;87:75-86

24 Genest J Jr., McNamara JR, MT, Salem DN, MD, Schaefer EJ, MD. Prevalence of Risk Factors in

Men with Premature Coronary Artery Disease. Am J Cardiol 1991;67:1185-1189 25 Genest J Jr., McNamara JR, Upson B, Salem DN, Ordovas JM, Schaefer EJ, Malinow MR.

Prevalence of Familial Hyperhomocyst(e)inemia in Men With Premature Coronary Artery Disease. Arteriosclerosis and Thrombosis, 1991;11:1129-1136

26 Genest J Jr., MD, Jenner JL, BSc, McNamara JR, MT, Ordovas JM, PhD, Silberman SR, PhD,

Wilson PWF, MD, Schaefer EJ, MD. Prevalence of Lipoprotein (a) [Lp(a)] Excess in Coronary Artery Disease. Am J Cardiol 1991;67:1039-1045

27 Qiu S, Théroux P, Genest J Jr, Solymoss BC, Robitaille D, Marcil M. Lipoprotein(a) Blood Levels in

Unstable Angina Pectoris, Acute Myocardial Infarction, and After Thrombolytic Therapy. Am J Cardiol 1991;67:1175-1179 [†]

28 Genest J Jr., Bard JM, Fruchart J-C, Ordovas JM, Wilson PWF, Schaefer EJ. Plasma

apolipoproteins A-I, A-II, B, E and CIII containing particles in men with premature coronary artery disease. Atherosclerosis 1991;90:149-157

29 Report of the Canadian Cardiovascular Society Consensus Conference on the Management of the

Postmyocardial Infarction Patient. Secondary Panel. Can Med Assoc J 1991;144:1015-1025 30 Campos H, Genest J Jr, Blijlevens E, McNamara JR, Jenner J, Ordovas JM, Wilson PWF, Schaefer

EJ. Low Density Lipoprotein Particle Size and Coronary Artery Disease. Arteriosclerosis and Thrombosis 1992;12:187-195 Selected as one of the 50 most often papers cited in ATVB (www.atvb.org).

31 Civeira F, Genest J, Pocovi M, Salem DN, Herbert PN, Wilson PWF, Schaefer EJ, Ordovas JM. The

MspI restriction fragment length polymorphism 3' to the apolipoprotein A-II gene: relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis 1992;92:165-176

32 Genest J Jr MD, McNamara JR MT, Ordovas JM PhD, Jenner JL BSc, Silberman SR PhD,

Anderson KM PhD, Wilson PWF MD, Salem DN MD, Schaefer EJ MD. Lipoprotein Cholesterol,


32

Apolipoprotein A-I and B and Lipoprotein(a) Abnormalities in Men With Premature Coronary Artery Disease. J Am Coll Cardiol 1992;19:792-802

33 Genest J. Jr., Malinow MR. Homocyst(e)ine and coronary artery disease. Current Opinion in

Lipidology, 1992;3:295-299 34 Sniderman AD, Genest J Jr. The measurement of apolipoprotein B should replace the conventional

lipid profile in screening for cardiovascular risk. Can. J. Cardiol 1992;8(2):133-140 35 Genest J Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Meyers RH, Silberman SR,

Wilson PWF, Salem DN, Schaefer EJ. Familial Lipoprotein Disorders in Patients With Premature Coronary Artery Disease. Circulation 1992;85:2025-2033

36 Genest J. Jr. Genetic Lipid Disorders in Cardiovascular Disease. Trends Cardiovasc Med

1992;2:140-145 [†] 37 Genest J Jr. Metabolic factors (other than LDL particles) and coronary artery disease. Can J

Cardiol 1993;9:15C-20C 38 Dufour R, Genest J Jr, Lupien PJ, Le Lorier J, Sniderman A, Boivin J-F, Demers D, Davignon J.

Diagnostic et traitement des dyslipidémies. Conseil consultatif de pharmacologie du Québec, Ministère de la Santé et des Services sociaux, Gouvernement du Québec, ISBN 2-550-27380-X

39 Genest J Jr, Bard J-M, Fruchart J-C, Ordovas JM, Schaefer EJ. Familial Hypoalphalipoproteinemia

in Premature Coronary Artery Disease. Arterioscler Thromb 1993;13:1728-1737 40 Schaefer EJ, Genest J Jr., Ordovas JM, Salem DN, Wilson PWF. Familial lipoprotein disorders and

premature coronary artery disease. Current Opinion in Lipidology 1993;4:288-298 41 Schaefer EJ, Genest J Jr., Ordovas JM, Salem DN, Wilson PWF. Familial lipoprotein disorders and

premature coronary artery disease. Atherosclerosis 1994;108:S41-S54 42 Carrier M, Pelletier GB, Genest J Jr., Cartier R, Leclerc Y, Pelletier LC. Cholesterol-Lowering

Intervention and Coronary Artery Disease After Cardiac Transplantation. Ann Thorac Surg 1994;57:353-356

43 Karayan L, Qiu S, Betard C, Dufour R, Roederer G, Minnich A, Davignon J, Genest J Jr. Response

to HMG CoA Reductase Inhibitors in Heterozygous Familial Hypercholesterolemia Due to the 10-kb Deletion ("French Canadian Mutation") of the LDL Receptor Gene. Arterioscler Thromb 1994;14:1258-1263 *

44 Rodriguez CR, Seman LJ, Ordovas JM, Jenner J, Genest J Jr, Wilson PWF, Schaefer EJ.

Lipoprotein(a) and coronary heart disease. Chem Phys Lipids 1994;67:389-98 45 Genest J, Frohlich J. A time to work, a time to teach, a time to learn. Can J cardiol 1994;10(B):3B-4B 46 Gagné E, Genest J Jr, Zhang H, Clarke LA, Hayden MR. Analysis of DNA Changes in the LPL

Gene in Patients With Familial Combined Hyperlipidemia. Arterioscler Thromb 1994;14:1250-1257 47 Blanchet C, Genest J Jr, Moisan J, Sauvé L, Schiffrin E. Rapport de l'enquête Santé Québec auprès

des Inuit du Nunavik. Santé Cardio-vasculaire. Montréal, Ministère de la Santé et des Services Sociaux du Québec. 1995 ISBN 2-551-13347-5

48 McNicoll S, Latour Y, Rondeau C, Bouthillier D, Davignon J, Genest J Jr. Cardiovascular risk factors

and lipoprotein profile in French Canadians with premature CAD: Impact of the National Cholesterol Education Program II guidelines. Can J Cardiol 1995;11:109-116 [*]


33

49 Fortin L-J, Genest J Jr. Measurement of Homocyst(e)ine in the Prediction of Arteriosclerosis. Clin Biochem 1995;28:155-162 [*]

50 Schaefer EJ, Jenner JJ, Seman L, McNamara JR, Contois JH, , Genest J Jr, Wilson PWF, Ordovas

JM. Lp(a) and coronary heart disease. In: Atherosclerosis X. Proceedings of the Xth International Symposium on Atherosclerosis. Woodford FP, Davignon J, Sniderman A, Editors. Elsevier eds. 1995, pp79-82

51 Genest J Jr, Cohn J. Clustering of Cardiovascular Risk Factors: Targeting High Risk Individuals.

Am J Cardiol 1995;75:8a-20a 52 Marcil M, Boucher B, Frohlich J, Davignon J, Solymoss BC, Genest J Jr.. Severe Familial HDL

deficiency (FHD) in French Canadian kindred: clinical, biochemical and molecular characterization. Arterioscler Thromb Vasc Biol 1995;15:1015-1024 [*]

53 Dalery K, Lussier-Cacan S, Selhub J, Davignon J, Latour Y, Genest J Jr. Homocysteine and

Coronary Artery Disease in French Canadian subjects: Relation With Vitamins B12, B6, Pyridoxal Phosphate and Folate. Am J Cardiol 1995;75:1107-1111 [*]

54 Fallen EL, Cairns J, Dafoe W, Frazure-Smith N, Genest J Jr., Massel D, Peretz D, Tremblay GJL,

Williams WL. Management of the postmyocardial infarction patient: A consensus report. Revision of the 1991 CCS Can J Cardiol 1995;11:477-486 Fallen EL, Cairns J, Dafoe W, Frazure-Smith N, Genest J Jr., Massel D, Peretz D, Tremblay GJL, Williams WL. Traitement des patients ayant subi un infarctus du myocarde. Rapport consensuel - Revision des lignes de conduite de la SCC formulées en 1991. Can J Cardiol 1995;11:659-669

55 Cohn JS, Tremblay M, Jacques H, Amiot M, Bouthillier D, Roy M, Genest J Jr, Davignon J.

Quantification of lipoprotein remnants in normolipidemic and hyperlipidemic subjects by measurement of plasma apolipoprotein E concentration in “remnant-sized” lipoproteins. Arterioscler Thromb Vasc Biol 1996;16:149-159

56 Marcil M, Boucher B, Davignon J, Gagné E, Hayden M, Genest J Jr. Lack of association of the apo

AI-CIII-AIV gene XmnI and SstI polymorphism and of the LPL gene mutations in familial combined hyperlipoproteinemia in French Canadian subjects. J Lipid Res 1996;37:309-319 [†]

57 Yu L, Qiu S, Genest J Jr. Abnormal regulation of low-density-lipoprotein receptor and 3-hydroxy-3-

methylglutaryl coenzyme A reductase gene expression in heterozygous familial hypercholesterolemia due to the "French Canadian mutation". Atherosclerosis 1996;124:103-117 [*]

58 Lussier-Cacan S, Selhub J, Pouliot A, Davignon J, Genest J Jr. Plasma total homocysteine in

healthy subjects: sex-specific relation with biological traits. Am J Clin Nutr 1996,64:587-93 (Editorial pp641-2)

59 Steiner G for the Diabetes Atherosclerosis Intervention Study (DAIS) project group. [Genest J, PI,

Montreal center]. The Diabetes Atherosclerosis Intervention Study (DAIS), A study conducted in cooperation with the World Health Organization. Diabetologica 1996;39:1655-1661

60 Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Rosenblatt D, Genest J Jr. Rozen R.

Correlation of a common mutation in methylenetetrahydrofolate reductase (MTHFR) with plasma homocysteine in patients with premature coronary artery disease. Arterio Thromb Vasc Biol 1997;17:569-573 [*] Selected as one of the most often papers cited in ATVB 2001;21:1093

61 Nguyen N-H, Reeves F, Therasse E, Latour Y, Genest J Jr. Percutaneous Transluminal Angioplasty

In Coronary-Internal Thoracic-Subclavian Steal Syndrome. Can J Cardiol 1997;13:285-289 [*] 62 Weber M, McNicoll S, Marcil M, Connelly P, Lussier-Cacan S, Davignon J, Latour Y, Genest J Jr.

Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and


34

apolipoprotein E phenotypes in premature coronary artery disease in French Canadians. Can J Cardiol 1997;13:253-260 [*]

63 Marcil M, Genest J Jr. Molecular Genetics of Lipoprotein Disorders in Premature Coronary Artery

Disease. Ninth International Symposium on Prospective Biology, Eurobiology. Galteau MM, Delwaite P, Siest G, Henny J, ed. Elsevier eds. 1997;123-128 [*]

64 Cianflone K, Zhang X-J, Sniderman A, Genest J Jr. Plasma Acylation-Stimulating Protein in

Coronary Artery Disease. Atheroscler Thromb Vasc Biol 1997:17:1239-1244 65 Grenier M-C, Gagnon K, Genest J Jr., Durand J, Durand L-G. Clinical comparison of acoustic and

electronic stethoscopes and design of a new electronic stethoscope. Am J Cardiol 1998;81:653-6 [*] 66 Batal R, Tremblay M, Krimbou L, Mamer O, Davignon J, Genest J Jr., Cohn JS. Familial deficiency

characterized by hypercatabolism of mature apo AI but not proapoAI. Atheroscler Thromb Vasc Biol 1998;18:655-664

67 Frohlich J, Fodor G, McPherson R, Genest J, Langner N. For the Health Canada Working Party on

the diagnosis and treatment of hypercholesterolemia and other dyslipidemias. Rationale for and outline of the Working Group on hypercholesterolemia and other dyslipidemias: Interim report. Can J Cardiol 1998;14:17A-22A

68 Wesolowska E, Marcil M, Lussier-Cacan S, Davignon J, Latour Y, Genest J. Jr. Angiotensin

Converting Enzyme Insertion/Deletion Polymorphism in French Canadian Subjects with Premature Coronary Artery Disease. Path Biol 1998;46(5):295-300 [*]

69 Minnich A, Baloukas J, Roederer G, Davignon J, Genest J Jr. Lipoprotein Lipase Gene Mutations In

Premature Coronary Artery Disease Can J Cardiol 1998;14:711-716 70 Genest J Jr, Marcil M. Genetics, Lipoproteins Disorders and Premature Coronary Artery Disease. XI

International symposium on atherosclerosis, Paris Oct 1997. Atherosclerosis XI 1998;10451053 [*] 71 Genest J Jr, Cohn J. Plasma triglyceride-rich lipoproteins and high density lipoprotein disorders

associated with atherosclerosis. Biomedicine ’98 Vascular Biology Symposium. J Invest Med 1998;46:351-358

72 Collins-Nakai R, Dagenais G, Bouchard C, Burgess E, Chockalingham A, Daniel L, Fodor G,

Frasure-Smith N, Genest J Jr., Gerstein, Igneszewski A, Keon W, MacLean D, McCrindle B, Paradis G, Petrasovits A, Phillips S, Pipe A, Reeder B, Reid B, Sniderman A, Tookenay V, Yusef S. Canadian Cardiovascular Society 1998 Consensus Conference on Coronary Heart Disease. Emerging Risk Factors Associated wth CAD: Homocysteine, Lipoprotien (a), Chylamydia Pneumonia and hemostatic factors. Can J Cardiol 1998

73 Bogaty P, Robitaille N-M, Dagenais GR, Solymoss S, Boyer L, Auger D, Labbe L, Simard S, Rail J,

Genest J Jr., Turgeon J. Atherogenic, hemostatic, and other potential risk markers in subjects with previous isolated myocardial infarction compared with long-standing uncomplicated stable angina. Am Heart J 1998;136:884-93

74 Davignon J, Genest J Jr. Genetic disorders of lipoproteins. Endocr Clin North Am 1998;27:521-549 75 Zhang XJ. Cianflone K. Genest J. Sniderman AD. Plasma acylation stimulating protein (ASP) as a

predictor of impaired cellular biological response to ASP in patients with hyperapoB. European Journal of Clinical Investigation. 1998;28:730-9

76 Marcil M, Yu L, Boucher B, Oram J, Genest J Jr. Cellular Cholesterol Transport and Efflux From

Fibroblasts is Abnormal in Subjects with Familial HDL Deficiency. Atheroscler Thromb Vasc Biol 1999;19:159-169 [*][MRC MT 15042]


35

77 Genest J Jr, Marcil M, Denis M, Yu L. High density lipoproteins in health and in disease. J. Invest

Med 1999;47:31-42 [*][MRC MT 15042] 78 Merouani A, Genest J Jr., Rozen R, Dubois J, Mitchell G, Lambert M, Robitaille P. Cerebrovascular

complications concommitant to severe homocysteinemia in a cystinotic patient on chronic dialysis. Press Pediatric Nephrol 1999;13:73-76 [MRC PA 15248]

79 Genest J Jr. Hyperhomocyst(e)inemia: determining factors and treatment. Vascular biology

working group 2. Can J Cardiol 1999. Can J Cardiol 1999;15b:35b-38b [MRC PA 15248] 80 Genest J Jr, Souliere V, Dufour R. Cholesterol-Lowering in Secondary Prevention of CAD: Treat-to-

Target, Percent Reduction, or Both? (Lessons learned from Recent Trials). Cardiovascular Disease Prevention 1999;2:7-12 [*]

81 Yu L, Ress E, Boucher B, Defesche JC, Kastelein J, Lavoie M-A, Genest J Jr. Familial

Hypercholesterolemia. Acceptor Splice Site (G-->C) Mutation in Intron 7 of the LDL-R Gene: Alternate RNA Editing Causes Exon 8 Skipping or a Premature Stop Codon in Exon 8. LDL-R Honduras-

1 [LDL-R1061(-1) G-->C ]. Atheroscler 1999;146:125-131 [*] 82 Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular

disease: a critical review of the epidemiologic evidence. Ann Int Med 1999;131:363-375 [MRC PA 15248]

83 Genest J Jr, Lavoie M-A. Homozygous familial hypercholesterolemia. Images in Clinical Medicine.

New Eng J Med 1999:341:490 84 Brooks-Wilson A, Marcil M, Clee S, Zhang LH, Romp C, van Dam M, Yu L, Brewer C, Collins J,

Molhuizen HOF, Loubser O, Francis-Ouelette BF, Fichter K, Ashbourne-Excoffon K, Sensen C, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, Morgan K, Koop, Pimstone S, Kastelein J, Genest J Jr, Hayden M. Mutations in the ATP binding cassette (ABC1) transporter gene in Tangier disease and Familial HDL deficiency (FHA). Nature Genet 1999;22:336-345 [Editorials in Nature Genet 1999;22:316; Science 1999;285:814 and Nature 1999;400:816] [MRC MT 15042]

85 Marcil M, Brooks-Wilson A, Clee S, Roomp K, Zhang LH, Collins J, Loobster O, Ouellette BFF,

Sensen CW, Fichter K, Yu L, Mott S, Denis M, Martindale D, Koop B, Pimstone S, Genest J Jr., Kastelein JJP, Hayden MR. Familial HDL Deficiency with defective cholesterol efflux is caused by mutations in cholesterol efflux regulatory protein (CERP/ABC1). Lancet 1999;354:1341-46 [Editorial Lancet 1999;9188:1402-3] [*][MRC MT 15042]

86 Weng X, Cloutier G, Solymoss BC, Genest J Jr. Contribution of G455A polymorphism at the β-

fibrinogen gene to erythrocyte aggregation in patients with premature coronary artery disease. Thromb Haemost 1999;82:1406-11 [*]

87 Genest J Jr. Emerging risk factors associated with cardiovascular diseases. Canadian

Cardiovascular Society 1998 Consensus Conference on the Prevention of Cardiovascular Diseases. Can I Cardiol 1999;15:73G-76G

88 Rahman P. Urowitz MB. Gladman DD. Bruce IN. Genest J Jr. Contribution of traditional risk factors to

coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 1999;26:2363-8 [MRC PA 15248]

89 Genest J Jr. Homocysteine and Coronary Artery Disease. In : Coronary Heart Disease: Reducing

the Risk; The scientific background for primary and secondary prevention of coronary heart disease. International Task Force for the Prevention of CAD. Nutrition, Metab and Cardiovasc Dis 1999;2 : Assman G, ed. [MRC PA 15248]


36

90 Genest J Jr, Nguyen N, Theroux P, Cohn JS. Effects of Micronized Fenofibrate on Plasma Lipoprotein Levels and Hemostatic Parameters in the Fed and Fasted States. J Cardiovasc Pharmacol 2000;35(1):164-72 [*]

91 Marcil M, Kastelein J, Hayden M, Genest J Jr. Mutations du gène de l’ATP Binding Cassette-1

(ABC-1) dans la maladie de Tangier et déficience familiale en HDL. Medecine Sciences 2000;16:421-3 [*][MRC MT 15042]

92 Cole D, Genest J, Lee N, Spence D. Homocyst(e)ine and Cardiovascular Disease. A statement for

health professionals. Can J Cardiol 2000, June 6 93 Mott S, Yu L, Marcil M, Boucher B, Rondeau C, Genest J Jr. Decreased Cellular Cholesterol Efflux

is a Common Cause of Familial Hypoalphalipoproteinemia; Role of the ABCA1 Gene Mutations. Atheroscler 2000;152;457-468 [*][MRC MT 15042]

94 Genest J. Dyslipidemias and Coronary Artery Disease. Can J Cardiol Suppl. 2000;16:suppl 3A- [†] 95 Fodor G, Frohlich J, Genest J Jr. McPherson R. Recommendations for the management and

treatment of dyslipidemias. Report of the working group on hypercholesterolemia and other dyslipidemias. Can Med Ass J 2000;162:1441-7

96 Title LM, Cummings PM, Giddens K, Genest J Jr., Nassar B. Effect of folic acid and antioxidants an

endothelial dysfunction. J Am Coll Cardiol 2000;36:758-65 [MRC PA 15248] 97 Devlin EE, Merouani A, Rozen R, Genest J Jr., Lambert M. Influence of methylenetetrahydrofolate

reductase genotype, age, vitamin B-12, and folate status on plasma homocysteine in children. Am J Clin Nutr. 2000 Dec;72(6):1469-73. [MRC PA 15248]

98 Hayden MR, Clee S, Brooks-Wilson A, Genest J Jr, Attie A, Kastelein J. Cholesterol Efflux

Regulatory Protein (CERP), Tangier Disease and Familial HDL Deficiency. Current Opinion Lipidol 2000;11:117-122 [†][MRC MT 15042]

99 Clee SM, Kastelein JJP, van Dam M, Marcil M, Roomp K, Zwarts KY, Collins JA, Roelants R,

Tamasawa N, Stulc T, Suda T, Ceska R, Boucher B, Rondeau C, Du Souich C, Brooks-Wilson A, Molhuizen HO, Frohlich J, Genest J Jr. Hayden MR. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease an ABCA1 heterozygotes. J Clin Invest 2000;106:1263-1270. [MRC MT 15042] [MRC DOP 40845]

100 Clee SM, Zwinderman AH, Engert JC, Zwarts KY, Molhuizen HOF, Roomp K, Jukema JW, van

Wijland M, van Dam M, Hudson TJ, Brooks-Wilson A, Genest J Jr, Kastelein JJP, Hayden MR. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease [MRC MT 15042]. Circulation 2001;103:r13-20

101 Bissonnette R, Treacy E, Rozen R, Boucher B, Cohn JS. Genest J Jr. Fenofibrate raises plasma

homocysteine in the fasted and fed states. Atheroscler 2001;155:455-462 [*][MRC PA 15248] 102 Haidar B, Mott S, Boucher B, Lee CY, Marcil M, Genest J Jr. Cellular Cholesterol Efflux is

Modulated by Phospholipid-Derived Signaling Molecules in Familial HDL Deficiency / Tangier Disease Fibroblasts. J Lipid Res 2001:42:249-257 [*][CIHR 15042; HSFC]

103 DAIS Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes:

the Diabetes Atherosclerosis Intervention Study, a randomized study. Steiner G [PI], Genest J. Jr. Montreal site PI. Steering committee. Lancet 2001;357:905-10

104 McPherson R, Angus C, Murray P, Genest J Jr. For the WATCH Investigators. Efficacy of

Atorvastatin in the Achievement of National Cholesterol Education Program LDL-Cholesterol Targets in Women with Severe Dyslipidemia: The Women’s Atorvastatin Trial on Cholesterol (WATCH). Am Heart J 2001;414:949-56


37

105 Merouani A, Lambert M. Delvin EE, Genest J Jr, Mitchell G, Robitaille P, Rozen R. Plasma

homocysteine concentrations in children with chronic renal failure. Pediatric Nephrology 2001;16:805-811 [MRC PA 15248]

106 Audelin M-C, Genest J Jr. Homocysteine and cardiovascular disease in diabetes mellitus.

Atheroscler 2001;159:497-511 [*][CIHR PA 15248] 107 Krimbou L, Marcil M, Davignon J, Genest J. Interaction of lecithin: cholesterol acyltransferase/α2

macroglobulin complex with low density lipoprotein receptor-related protein (LRP). Evidence for an LRP/α2 MR-mediated sytem participating in LCAT clearance. J Biol Chem 2001;276:33241-48 DOI10.1074/jbc.M100326200 [*][CIHR MOP 15042; CIHR DOP 40845]

108 Kramer MS, Goulet L, Lydon J, Seguin L, McNamara H, Dassa C, Platt RW, Chen MF, Gauthier H,

Genest J, Kahn S, Libman M, Rozen R, Masse A, Miner L, Asselin G, Benjamin A, Klein J, Koren G. Socio-economic disparities in preterm birth: causal pathways and mechanisms. Paediatr Perinat Epidemiol. 2001 Jul;15 Suppl 2:104-23.

109 O’Connell Genest J Jr.. High Density Lipoproteins and endothelial function. Circulation

2001;104:1978-1983 [*][CIHR MOP 15042] 110 Zha X, Genest J Jr., McPherson R. Endocytosis is enhanced in Tangier Fibroblasts: possible role of

ABCA1 in endosomal vesicular transport. J Biol Chem 2001;276(42):39476-83 [MRC MOP 15042] [HSFC] DOI10.1074/jbc.M105067200

111 Genest J. Genetics and Prevention: A new look at HDL cholesterol. Cardiol Rev. 2002 Jan-

Feb;10(1):61-71 [CIHR MOP 15042; HSFC] [†] 112 Merouani A Delvin EE, Genest J, Rozen R, Lambert M. Merouani A, Plasma homocysteine

concentration changes after renal transplantation in children. Ped Nephrol 2002;17:520-523 113 Merouani A, Rozen R, Clermont MJ, Genest J. Renal function, homocysteine, and other plasma thiol

concentrations during the postrenal transplant period. Transplant Proc. 2002 Jun;34(4):1159-60. 114 Wellington C, Yang Y-Z, Kwok A, Whitton A, Clee SM, Zwartz K, Newman S, Roomp K, Sinjaraja R,

Zhang L-H, Tafuri S, Kastelein J, Genest J, Hayden MR. Truncation mutations in human ABCA1 suppress normal upregulation of wild type ABCA1 by 9-cis-retinoic acid and 22-OH cholesterol. J Lipid Res 2002;43:1939-49 [CIHR MOP 15042]

115 Klerk M, Verhoef P, [Genest J Jr et al., coll] The MTHFR Collaboration Study. Pooled analysis on

MTHFR C677T polymorphism and risk of coronary artery disease. Accepted, J Am Med Ass 2002;288:2023-2031 (Collaborator) [Editorial JAMA 2002;288:2042-3]

116 Homocysteine Studies Collaborations. Clarke R, Lewington S, Donald A, Collins R. [Genest J et al,

coll.]. Homocysteine and risk of ischemic heart disease and stroke: 6000 events among 17,000 adults in 30 observational studies. J Am Med Ass 2002;288:2015-2022 (Coll.) [Editorial JAMA 2002;288:2042-3]

117 Genest J. Novel Insights on HDL in Coronary Heart Disease. Int J Clin Practice (Suppl) 2002;130:17-

22 [†] 118 Haidar B, Denis M, Krimbou L, Marcil M, Genest J Jr. Cyclic AMP induces ABCA1 phosphorylation

activity and promotes cholesterol efflux from fibroblasts. J Lipid Res 2002;2087-2094 [CIHR MOP 15042] [*]

119 Lee CY, Krimbou L, Boucher B, Bernard C, Laramée P, Genest J, Marcil M. Compound

Heterozygocity at the Sphingomyelin Phosphodiesterase-1 (SMPD-1) gene is Associated with a low HDL cholesterol. Hum Genet 2003;112:552-562 e-pub 12607113[CIHR MOP 15042] [*]


38

120 Schwahn BC, Chen Z, Laryea MD, Wendel U, Lussier-Cacan S, Genest J. Jr., Mar M-H, Zeisel

SH, Castro C, Garrow T, Rozen R. Homocysteine-betaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency The FASEB Journal 2003;17:512-4 Express Article 10.1096/fj.02-0456fje Published online January 22, 2003

121 Zha X, Gauthier A, Genest J, McPherson R. Secretory Vesicular Transport is Altered during ABCA1-

Mediated Cholesterol Efflux. J Biol Chem 2003;278:10002-5 10.1074/jbcc300024200x [CIHR MOP 15042]

122 Marcil M, Bissonnette R, Vincent J, Krimbou L, Genest J. Cellular phospholipid and cholesterol efflux

are major determinants of initial lipidation of high-density. Circulation 2003;107:1366-1371 [CIHR MOP 15042; CIHR DOP 40845; HSFC] [*]

123 Sniderman AD, Zhang ZJ, Genest J, Cianflone K. The effects on apo B100 secretion and bile acid

synthesis by increasing cholesterol efflux from HepG2 cells by apo AI, HDL or cyclodextrin. J Lipid Res 2003:44:527-532 [CIHR MOP 15042]

124 Genest J. Lipoprotein disorders and cardiovascular risk. J Inherited Metabolic Disease 2003;26:267-

287 [†] [CIHR MOP 15042] 125 Denis M, Bissonnette R, O’Connell B, Haidar B, Krimbou L, Bouvier M, Genest J Jr, Expression,

regulation and activity of ABCA1 in human cell lines. Mol Genet Metab 2003 2003;78:265-274 [CIHR MOP 15042; CIHR DOP 40845; HSFC] [*]

126 Ridker PM for the JUPITER Study Group (Genest J, co PI). Rosuvastatin in the primary prevention

of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003;108(19):2292-7

127 Krimbou L, Marcil M, Chiba H, Genest J. Structural and functional properties of human high density

lipoproteins containing only apoE particles (HDL-LpE). J Lipid Res 2003;44:884-892 e-pub12611904 [CIHR MOP 15042; HSFC][*]

128 Genest J, Pedersen TR. Prevention of cardiovascular ischemic disease: high-risk and secondary

prevention. Circulation 2003;107:2059-1065 [†]. 129 Essebag V, Genest J. Suissa S, Pilote, L. The nested case-control study in cardiology. Am Heart

Journal 2003;146:581-90 130 Genest J, Frohlich J, Fodor G, McPherson R. Guidelines for the management and treatment of

dyslipidemia and prevention of cardiovascular disease. On behalf of the working group on hypercholesterolemia and other dyslipidemias. Can Med Ass J 2003;169:921-4 (full text e-pub) www.cmaj.ca/cgi/content/full/169/9/21/DC1

131 Denis M, Haidar B, Marcil M, Krimbou L, Genest J. Molecular and cellular physiology of

apolipoprotein A-I lipidation by the ATP biding cassette A1 (ABCA1). J Biol Chem 2004:279:7384-7394 (published December 4, 2003 as doi:10.1074/jbc.M306963200) [*] [CIHR MOP 15042]

132 Haidar B, Denis M, Marcil M, Krimbou L, Genest J. Apolipoprotein A-I activates cellular camp

signaling through the ABCA1 receptor. Evidence for molecular interactions between ABCA1 receptor and G protein. J Biol Chem 2004;279:9963-9. (published 29 Dec 2003 as 10.1074/jbc.M313487200) [*] [CIHR MOP 15042]

133 Genest J. Preventive Cardiology: Move over LDL-C, Hello CRP? Can J Cardiol 2004,suppl B:89B-

92B


39

134 Alenezi M, Marcil M, Blank D, Sherman M, Krimbou L, Genest J. Is The Low HDL-C Frequently Seen In The Metabolic Syndrome, Due To Cellular Lipid Efflux Defect? J Clin Endo Metab 2004;89:761-764 [*] [CIHR MOP 15042] [CIHR MOP 62834]

135 Genest J, Frohlich J, Steiner G. Effect of fenofibrate-mediated increase in plasma homocysteine on

the progression of CAD in type 2 diabetes. Am J Cardiol 2004;93:848-853 136 Marcil M, O’Connell B, Genest J. High-density lipoproteins: Multifunctional vangards of the

cardiovascular system. Expert Rev Cardiovasc Ther 2004;2:417-430 [CIHR MOP 15042] [CIHR MOP 62834] [†]

137 Krimbou L, Haidar B, Denis M, Marcil M, Genest J. Molecular interactions between apolipoprotein E

and ABCA1 : Impact on apoE lipidation. J Lipid Res 2004;45:839-848 (e-pub 01.feb.2004) [CIHR MOP 15042] [HSFC] [†]

138 Denis M, Haidar B, Marcil M, Bouvier M, Krimbou L, Genest J. Characterization of oligomeric human

ATP binding cassette transporter A1. Potential implication for determining the structure of nascent HDL particles. [CIHR MOP 15042][*] J Biol Chem 2004;279:41529-41536 Jul 26 [Epub] 15280376

139 O’Connell B, Denis M, Genest J. Cellular physiology of cholesterol efflux in vascular endothelial cells.

Circulation 2004;110(18):2881-2888. [CIHR MOP 62834] [CIHR MOP 15042][*] 140 Alenezi M, Genest J, Marcil M. High Density Lipoproteins: Target for Cardiovascular Disease

Prevention. Drug Therapy 2004;1:159-164 [CIHR MOP 15042] [CIHR MOP 62834] [†] 141 Dorval J-F, Anderson T, Buithieu J, Shan S, Hutchison S, Huyhn T, Jobin J, Lonn E, Poirier J, Title L,

Walling A, Charbonneau F, Genest J. Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with CAD. Am J Cardiol 2005;95:249-253 [*]

142 Alawadhi M, Thanassoulis G, Marcil M, Genest J. Genetics of Coronary Atherosclerosis. Current

Atheroscler Rep 2005;7:196-203 [CIHR MOP 62834] [†] 143 Genest J, McPherson R, Frohlich J, Fodor G. The analysis by Manuel and colleagues creates

controversy with headlines, not data. Can Med Ass J 2005;172:1033-4 144 Lee C-Y, Lesimple A, Larsen A, Mamer O, Genest J. Electron spray ionization – mass spectroscopy

quantitation of increased sphingomyelin in Niemann-Pick disease B HDL. J Lipid Res 2005;46(6)1213-1228 e-pub 15741650 [CIHR MOP 15042] [*]

145 Krimbou L, Hassan HH, Blain S, Rashid S, Denis M, Marcil M, Genest J. Biogenesis and speciation

of nascent apo AI – containing particles in various cell lines. J Lipid Res 2005;46:1668-1677 [CIHR MOP 15042] [*]

146 White W, Haddad H, LeBlanc M-H, Giannetti N, Pfugfelder P,Davies R,Isaac D, Burton J, Chan M,

Azevedo E, Howlett J, Ignaszewski A, Busque S, Cantarovich M, Ferguson R, Genest J, Ross H Conversion from Cyclosporine microemulsion to Tacrolimus-based Immunoprophylaxis Improves Cholesterol Profile in Heart Transplant Recipients with Treated but Persistent Dyslipidemia. The Canadian Multicentre Randomized Trial of Tacrolimus vs. Cyclosporine microemulsion. J Heart Lung Transplant 2005;24(7):798-809

147 Hassan HH, Blain S , Boucher B, Denis M, Krimbou L, Genest J. Structural Modification of Plasma

HDL by Phospholipids Promotes Efficient ABCA1-mediated Cholesterol Release. J Lipid Res 2005;46:1457-65 [CIHR MOP 15042] [*]

148 Bourgault, Davignon J, Fodor G, Gagné C, Gaudet D, Genest J, Lavoie, M-A, Leiter L, McPherson

R, Sénécal M, Marentette M, Sebaldt R. Statin therapy in Canadian patients with hypercholesterolemia: the CALIPSO study. Can J Cardiol 2005;21:1187-93


40

149 Lee C-Y, Vincent J, Lesimple A, Larsen Å, Laliberté J, Denis M, Mamer O, Krimbou L Genest J, Marcil M. Increased sphingomyelin content of HDL impairs HDL biogenesis and maturation in human Niemann-Pick Disease Type B. J Lipid Res 2006;47:322-332. [CIHR MOP 15042] [CIHR MOP 62834] [HSFC] [*]

150 E. Lonn, C. Held, J.M.O. Arnold, J. Probstfield, M.J. McQueen, M. Micks, J. Pogue, P. Sheridan, J.

Bosch, J. Genest, S. Yusuf. Rationale, Design and Baseline Characteristics of a Large, Simple, Randomized Trial of Combined Folic Acid and Vitamins B6 and B12 in High-Risk Patients. The Heart Outcomes Prevention Evaluation (HOPE) –2 Trial. The HOPE-2 Investigators*. Can J Cardiol 2006;22:47-53

151 Dastani Z, Dangoisse C, Boucher B, DesBiens K, Dufour R, Hegele R, Paivi Pajukanta, Jamie

Engert, Krimbou L, Genest J, Marcil M. A Novel Mutation of Apolipoprotein AI (Apo AIE136X) Causes a low HDL-C in French Canadians. Atheroscler 2006;185(1):127-136 [CIHR MOP 62834] [*]

152 Dastani Z, Quiogue L, Engert JC, Plaisier C, Marcil M, Genest J, Pajukanta P. Evidence of a gene

influencing HDL-C on chromosome 4q31.21. Atheroscler Thromb Vasc Biol 2006;26(2):392-7 [*] [CIHR MOP 62834] Dec 1 e-pub PMID 16322534

153 Hobbs FD, Gensini G, Mancini JB, Manolis AJ, Bauer B, Bohler S, Genest J, Feldman R, Harvey P,

Jenssen TG, Metclafe M, Marques da Silva P, on behalf of the Jewel investigators. Rationale and design for an iInternational, open-label program to assess the effectiveness of a single pill (amlodipine / atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL I and II studies): Int J Cardiol. 2006;110(2):242-50

154 Alrasadi K, Ruel I, Marcil M, Genest J. Functional mutations in the ABCA1 gene in subjects of French

Canadian descent with HDL deficiency. Atheroscler 2006;188:281-291 [CIHR MOP 62834] [*] 155 Hassan HH, Denis M, Krimbou L, Genest J. Cellular cholesterol homeostasis in vascular endothelial

cells. Can J Cardiol 2006;22:35B-40B suppl [CIHR MOP 15042] [*] 156 Mikael LG, Genest J, Rozen R. Elevated homocysteine reduces expression of apolipoprotein AI in

hyperhomocysteinemic mice and in males with coronary artery disease.Circulation Research 2006;98:564-71 [CIHR MOP 15042]

157 Clarke R et al. (Genest J, collaborator) Homocysteine-lowering trials for the prevention of

cardiovascular events: A review of the designs and power of large randomized trials. B-vitamins treatment trialists. Am Heart J 2006;151:282-87

158 White M, Ross H, Haddad H, Leblanc M-H, Racine N, Plugfelder P, Giannetti N, Davies R, Azevedo

E, Isaac D, Burton J, Ferguson R, Genest J. Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus. Transplantation, 2006;82:763-770

159 Genest J. Combination of Statin and Ezetimibe for the Treatment of Dyslipidemias and the

Prevention of Coronary Artery Disease. Can J Cardiol 2006;10:863-868 160 The HOPE-2 Investigators. E. Lonn, S. Yusuf, J. M. O. Arnold, P. Sheridan, M. J. McQueen, J.

Pogue, J. Probstfield, G. Fodor, C. Held, M. Micks, Genest J. Jr.. Homocysteine lowering with folic acid and B vitamins in vascular disease: The Heart Outcomes Prevention Evaluation (HOPE) -2 Trial. New Eng J Med 2006,17;355(7):746

161 Dastani Z, Engert JC, Genest J, Marcil M. Genetics of High-Density Lipoproteins. Curr Op Cardiol

2006;21:329-335 [CIHR MOP 62834] [†] 162 Marcil M, Vu H, Cui W, Dastani Z, Engert J, Gaudet D, Castro-Cabezas M, Sniderman AD, Genest J,

Cianflone K. Identification of a C5L2 mutation in a Québec family. Atheroscler Thromb Vasc Biol 2006; 26: 1619-1625 [CIHR MOP 62834] [*]


41

163 Krimbou L, Marcil M, Genest J. New Insights Into the Biogenesis of Human High Density Lipoprotein.

Curr Op Lipidol 2006;17:258-267 [CIHR MOP 15042] [†] 164 McPherson R, Frohlich J, Fodor G, Genest J. Canadian Cardiovascular Society position statement:

recommendations for the diagnosis and treatment of dyslipidemias and prevention of cardiovascular disease. Can J Cardiol 2006;22:913-927

165 Leiter L, Genest J, Harris SB, Lewis G, McPherson R, Steiner G, Woo V. Dyslipidemia in adults with

diabetes: Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Can J Diab 2006;30(3):230-240

166 Hassan HH, Denis M, Nyholt D, Lee D-Y D, Iatan I, Ruel I, Krimbou L, Genest J. Identification of an

ABCA1-dependent phospholipid-rich plasma membrane apolipoprotein A-I binding site for nascent HDL biogenesis J Lipid Res. 2007;48:2428-42 e-pub july 26.2007) [*] [CIHR MOP 15042].

167 Villeneuve J, Lamarre D, Vanier M-C, Lussier M-T, Genest J, Hudon E, Blais L, Perreault S, Lalonde

L. How to help patients manage dyslipidemies: A primary care physician-pharmacist team intervention. Can Pharn J 2007;140:300-6 [CIHR TEAM Study Lalonde L, PI]

168 Ridker PM, Danielson E, Fonseca FAH, Genest j, Gotto AM, Kastelein JJP, Koenig W, Libby P,

Lorenzatti A, MacFadyen J, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ on behalf of the JUPITER Trial Study Group. Baseline Characteristics of Participants in the JUPITER Trial, a Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals with Low LDL-C and Elevated hsCRP. Am J Cardiol 2007;100:1659-1664

169 Grenon SM, Lachapelle K, Marcil M, Omeroglu A, Genest J, de Varennes B.Surgical strategies for

severe. calcification of the aorta (porcelain aorta) in two patients with homozygous familial hypercholesterolemia. Can J Cardiol. 2007;23:1159-61 [*]

170 Rashid S, Genest J. The Effect of Obesity on High Density Lipoprotein Metabolism. Obesity

2007;15:2875-2888 [CIHR MOP 15042] [*] 171 Lee C-Y, Tamura T, Rabah N, Sheppard P, Jain M, Laporte F, Krimbou L, Lazure C, Wada I, Genest

J. The carboxyl-terminal disulfide bond of acid sphingomyelinase is critical to its secretion and enzymatic function. Biochemistry 2007 Dec 25;46(51):14969-14978 [CIHR MOP 62834] [*]

172 Dastani Z, Ruel IL, Dangoisse C, Engert JC, Genest J, Marcil M. Sphingomyelinase

Phosphodiesterase-1 (SMPD-1) Gene Polymorphisms and Haplotype analysis in Low HDL cholesterol French Canadian Population. BMC Medical Genetics 2007;8:79 [CIHR MOP 62834] [*]

173 Ray JG, Lonn E, Yi Q, Rathe A, Sheridan P, Kearon C; HOPE-2 investigators, Yusuf S, Arnold MJ,

McQueen MJ, Pogue J, Probstfield J, Fodor G, Held C, Micks M, Genest J Jr. Venous thromboembolism in association with features of the metabolic syndrome. QJM. 2007 100(11):679-84.

174 Charbonneau F, Anderson TJ, Title LM, Huynh T, Chan SY, Jobin J, Walling AD, Hutchison SJ,

Dorval JF, Tran T, Lonn E, Genest J. Incremental Effect of Amlodipine and Atorvastatin on Endothelial Function and Markers of Cardiovascular Risk (MARGAUX trial). Atheroscler 2008:197:420-27 [*]

175 Krimbou L, Ruel I, Dastani Z, Alrasadi, Hajj Hassan H, Iatan I, Marcil M, Genest J. Disorders of HDL

Biogenesis. Annals Medicine. 2008;40:1;39-47 [CIHR MOP 62834] [CIHR MOP 15042] [†] 176 Awan Z, Alrasadi K, Francis GA, Hegele RA, McPherson R, Frohlich J, Valenti D, de Varennes B,

Marcil M, Gagné C, Genest J, Couture P. Vascular Calcifications in Homozygote Familial Hypercholesterolemia. Atheroscler Thromb Vasc Biol 2008;28:777-785 [CIHR MOP 62834] [CTP 82946] [*]


42

177 Hassan HH, Bailey D, Denis M, Lee D-Y D, Iatan I, Ruel I, Krimbou L, Genest J. Quantitative

analysis of ABCA1-dependent compartmentalization and trafficking of apo AI: implications for current models of HDL biogenesis. J Biol Chem 2008;283:11164-75 [CIHR MOP 15042] [*]

178 Iatan I, Alrasadi K, Ruel I, Alwaili K, Genest J. Effect of ABCA1 Mutations on Risk for Myocardial

Infarction. Curr Atheroscler Rev 2008;10:413-26 [CIHR MOP 62834] [†] 179 Awan Z, Al Waili K, Alrasadi K, Genest J. Treatment of low High density lipoprotein cholesterol. Can

J Cardiol 2008;24:27-31C [CIHR MOP 15042] [†][*] 180 Lee JC, Weissglas-Volkov D, Kyttälä M, Dastani Z, Cantor RM, Sobel E, Plaisier C, Engert JC, van

Greevenbroek MMJ, Kane JP, Malloy MJ, Pullinger CR, Huertas-Vazquez A, Aguilar-Salinas CA, Tusie- Luna T, Tjerk de Bruin WA, Aouizerat BE, van der Kallen C, Croce C, Aqeilan R, Marcil M, Viikari JS, Lehtimäki T, Raitakari OT, Kuusisto J, Laakso M, Taskinen MR, Genest J, Pajukanta P. Identification of WW domain-containing oxidoreductase as a novel HDL-C susceptibility gene. Am J Hum Genet 2008 2008;83:180-92 [CIHR MOP 62834] [*]

181 Alrasadi K, Awan K, Ruel I, Hafiane A, Marcil M, Krimbou L, Genest J. Comparison of Treatment of

Severe High-Density Lipoprotein Cholesterol Deficiency in Men with Daily Atorvastatin (20 mg) versus Fenofibrate (200 mg) versus Extended Release Niacin (2 g). Am J Cardiol 2008;102:1341-7 [CIHR MOP 62834] [CIHR MOP 15042]

182 Leiter L, Genest J, Harris SB, Lewis G, McPherson R, Steiner G, Woo V. Dyslipidemia. Canadian

Diabetes Association Clinical Practice Guidelines Expert Committee. Can J Diab 2008;32(suppl 1):S107-S114

183 Cannon CP,Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA,

McCabe CH, Veltri E, Braunwald E, Califf RM; IMPROVE-IT Investigators (Genest J). Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156(5):826-32

184 Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby P,

Lorenzatti AJ, MacFayden J, Nordestgaar BG, Shepherd J, Willerson JT, Glynn R. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New Eng J Med 2008;358:2195-2207. Editorial NEJM 2008;359:2280

185 Sénécal M, Fodor G, Gagné, C, Genest J, Lavoie M-A, McPherson R, Marentette M, Sebaldt RJ.

Limitations of Statin Monotherapy for the Treatment of Dyslipidemia - a projection based on the Canadian Lipid Study Observational (CALIPSO). Curr Med Res Opinion 2009;25:47-55

186 Alrasadi K, Alwaili K, Awan Z, Valenti D, Marcil M, Genest J. Aortic calcifications in familial

hypercholesterolemia: potential role of the low-density lipoprotein receptor gene. Am Heart J 2009;157:170-6. [*] [CIHR MOP 62834] [CTP 82946]

187 Kahn SR, Platt R, McNamara H, Rozen R, Chen MF, Genest J Jr, Goulet L, Lydon J, Seguin L,

Dassa C, Masse A, Asselin G, Benjamin A, Miner L, Ghanem A, Kramer MS. Inherited Thrombophilia and Preeclampsia within a Multicenter Cohort: The Montreal Preeclampsia Study. Am J Obstet Gynecol. 2009;200(2):151.e1-9; editorial p121 discussion e1-5 Dec 12

188 Alwaili K, Alrasadi K, Awan Z, Genest J. Approach to the Diagnosis and Management of Lipoprotein

Disorders. Curr Opin Endocrilon Diabetes Obes. 2009;16:132-140 [†] [*][CIHR MOP 62834] 189 Glynn RJ, Danielson E, Fonseca FAH, Genest J, Gotto MA, Kastelein JJP, Koenig W, Libby P,

Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM. A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism: the JUPITER Trial. NEJM 2009;360:1851-61


43

190 Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby P,

Lorenzatti AJ, MacFayden J, Nordestgaar BG, Shepherd J, Willerson JT, Glynn R. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373:1175-82.

191 Kramer MS, Lydon J, Séguin L, Goulet L, Kahn SR, McNamara H, Genest J, Dassa C, Chen MF,

Sharma S, Meaney MJ, Thomson S, Van Uum S, Koren G, Dahhou M, Lamoureux J, Platt RW. Stress Pathways to Spontaneous Preterm Birth: The Role of Stressors, Psychological Distress, and Stress Hormones. Am J Epidemiol. 2009;169(11);1319-26

192 Hobbs RFD, Gensini G, John Mancini GB, Manolis AJ, Bauer B, Genest J, Feldman RD, Harvey P,

Jenssen TG, da Silva PM; for the JEWEL Study Group. International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. Eur J Cardiovasc Prev Rehabil 2009;16(4):472-80

193 Kinzler WL, Prasad V, Ananth CV; (Ananth CV, Getahun D, Srinivas N, DeMarco C, Elsasser D, Lai

YL, Pitts S, Smulian JC, Kinzler WL, Peltier MR, Lake M, Philipp C, Rhoads GG, Moore DF, Genest J, Shen-Schwarz S, Prasad V). New Jersey-Placental Abruption Study Investigators. The effect of maternal thrombophilia on placental abruption: histologic correlates. J Matern Fetal Neonatal Med. 2009;22(3):243-8

194 Peltier MR, Ananth CV, Oyelese Y, Vintzileos AM; (Ananth CV, Getahun D, Srinivas N, DeMarco C,

Elsasser D, Lai YL, Pitts S, Smulian JC, Kinzler WL, Peltier MR, Lake M, Philipp C, Rhoads GG, Moore DF, Rozen R, Genest J, Shen-Schwarz S, Prasad V)New Jersey-Placental Abruption Study Investigators. Thromboembolic diseases in families of women with placental abruption. Epidemiology. 2009 Sep;20(5):733-7

195 Kramer MS, Kahn SR, Rozen R, Evans R, Platt RW, Chen MF, Goulet L, Séguin L, Dassa C, Lydon

J, McNamara H, Dahhou M, Genest J. Vasculopathic and thrombophilic risk factors for spontaneous preterm birth. Int J Epidemiol. 2009;38(3):715-23

196 Abourbih S, Filion KB, Joseph L, Schiffrin E, Rinfret S, Poirier P, Pilote L, Genest J, Eisenberg MJ.

Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review of Randomized Controlled Trials. Am J Med. 2009;122(10):962.e1-8.

197 Rashid S, Marcil M, Ruel I, Genest J. Identification of a novel human cellular HDL biosynthesis

defect. Eur Heart J 2009; 30(18): 2204-12 [*] [CIHR MOP 15042] [CIHR MOP 62834] 198 Iatan I, Dastani Z, Do R, Ruel I, Marcil M, Bailey SD, Krimbou K, Prat A, Seidah NG, Engert JC,

Genest J. Genetic Variability at the PCSK5 Influences HDL-C levels Circulation cardiovasc Genet 2009;2:467-475 [*] [CIHR MOP 62834] [CTP 82946]

199 Kramer MS, Kahn SR, Platt RW, Genest J, Rozen R, Chen MF, Goulet L, Séguin L, Dassa C, Lydon

J, McNamara H, Dahhou M, Lamoureux J, Evans RW. Antioxidant Vitamins, Long-Chain Fatty Acids, and Spontaneous Preterm Birth. Epidemiology 2009; 20(5):707-13

200 Bousette N, D’Orleans-Juste P, Al-ramli W, You Z, Genest J, Qureshi ST, Kiss RS, Gramolini A, Behm D, Ohlstein EH, Harrison SM, Douglas SA, Giaid A. Urotensin II receptor knockout mice on an apoE knockout background fed on a high fat diet exhibit enhanced hyperlipidemic and atherosclerotic phenotype. Circ Res. 2009;105(7):686-95

201 Villeneuve J, Lamarre D, Lussier MT, Vanier MC, Genest J, Blais L, Hudon E, Perreault S, Berbiche

D, Lalonde L. Physician-pharmacist collaborative care for dyslipidemia patients: Knowledge and skills of community pharmacists. J Contin Educ Health Prof. 2009 Dec 8;29(4):201-208


44

202 Genest J, Frohlich J, McPherson R, Anderson T, Couture P, Fodor G, Gupta M, Lau DC, Leiter L, Lonn E, Campbell N, Carpentier A, Dufour R, Francis GA, Grover S, Hegele RA, Mancini GBJ, Ng D, Pearson GJ, Sniderman AD, Stone J, Ur E. Guidelines for the diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease 2009. Can J Cardiol.2009:25:567-579

203 Ridker PM, MacFadyen JG, Fonseca FAH, Genest J, Gotto MA, Kastelein JJP, Koenig W, Libby P,

Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson T, Glynn RJ for the JUPITER Study Group. Number Needed To Treat with Rosuvastatin to Prevent Cardiovascular Events and Death Among Men and Women with Low LDL Cholesterol and Elevated hsCRP: The JUPITER Trial. ICirculation: Cardiovasc Quality Outcomes 2009;2(6):816-823

204 Awan Z, Bailey D, Hafiane A, Genest J. Severe acquired hypercholesterolemia and

hypoalphalipoproteinemia. J Clin Lipidol 2009;3:393-397 [CIHR MOP 15042] [*]

205 Dubuc G, Tremblay M, Pare G, Jacques H, Hamelin J, Benjannet S, Boulet L, Genest J, Bernier L, Seidah NG, Davignon J. A new method for measurement of total plasma PSCK9 - clinical applications. J Lipid Res. 2010;51:140-9

206 Dastani Z, Pajukanta P, Marcil M, Rudzicz N, Ruel I, Bailey SD, Lee JC, Lemire M, Faith J, Platko J,

Rioux J, Hudson TJ, Gaudet D, Engert JC, Genest J. Fine mapping and association studies of a high-density lipoprotein cholesterol linkage region on chromosome 16 in French-Canadian subjects. Eur J Hum Genet 2010;18(3):342-7 [*] [CIHR MOP 62834]

207 Kramer MS, Kahn SR, Platt RW, Genest J, Chen MF, Goulet L, Séguin L, Lydon J, McNamara H,

Libman M, Dahhou M, Lamoureux J, Skogstrand K, Thorsen P, Mid-trimester maternal plasma cytokines and CRP as predictors of spontaneous preterm birth. Cytokines 2010;49(1):10-14

208 Villeneuve J, Genest J, Blais L,M-C, Lamarre D, Marc Fredette M, Lussier M-Y, Perreault S, Eveline

Hudon E, Berbiche D, Lalonde L. A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: TEAM study. [CIHR MCT-133732-RCT][ISRCTN Register; registration number: ISRCTN66345533], CMAJ 2010;182(5):447-55

209 Bailey D, Ruel I, Cochrane H, Hafiane A, Jauhiainen M, Ehnholm C, Krimbou L, Genest J. Analysis

of Lipid Transfer Activity between Model Nascent HDL Particles and Plasma Lipoproteins: Implications for Current Concepts of Nascent HDL Maturation and Genesis J Lip Res 2010 Apr;51(4):785-97 [CIHR MOP 15042] [*]

210 Genest J. C-Reactive protein: Risk factor, Biomarker and/or Therapeutic Target? Can J Cardiol

2010;26(suppl):41-44A

211 Alwaili K, Awan Z, Alshahrani A, Genest J. High-Density Lipoproteins and Cardiovascular Disease: Update 2010. Expert Rev Cardiovasc Ther. 2010;8(3):413-23. [†][*][CIHR MOP 15042] [CIHR MOP 62834]

212 Bailey D, Jahagirdar R, Gordon A, Hafiane A, Campbell S, Shatur S, Wagner GS, Hansen HC,

Chiacchia FS, Johansson J, Krimbou L, Wong NCW, Genest J. RVX-208: A Small Molecule That Increases Apolipoprotein A-I and High-Density Lipoprotein Cholesterol In Vitro and In Vivo. J Am Coll Cardiol 2010; 55: 2580-2589. [†][*][CIHR MOP 15042]

213 Mora S, Glynn RJ, Hsia J, Macfadyen JG, Genest J, Ridker PM. Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia. Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women From Primary Prevention Trials. Circulation. 2010 Mar 9;121(9):1069-77.

214 Mottillo S, Filion KB, Bélisle P, Joseph L, Genest J, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ . The metabolic syndrome: a systematic review and meta-analysis JACC 2010;56(14):1113-32


45

215 Ridker P, Genest J, Boekholdt SM, Libby P, Gotto , Brno, Mora S, MacFadyen J, Glynn R, Kastelein

JJ. High Density Lipoprotein Cholesterol and Risk of First Cardiovascular Events After Treatment with Potent Statin Therapy. Lancet. 2010;376(9738):333-9

216 Ridker PM, MacFadyen J, Nordestgaard BG, Koenig W, Kastelein JL, Genest J, Glynn RJ.

Rosuvastatin for Primary Prevention Among Individuals with Elevated hsCRP and 5 to 10 and 10 to 20 Percent 10-Year Risk: Implications of the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial for “Intermediate Risk”. Circulation: Cardiovascular Outcomes and Quality 2010 Sep;3(5):447-52

217 Elsasser DA, Ananth CV, Prasad V, Vintzileos AM (Genest J); New Jersey-Placental Abruption Study Investigators. Diagnosis of placental abruption: relationship between clinical and histopathological findings. Eur J Obstet Gynecol Reprod Biol. 2010;148(2):125-30. Epub 2009 Nov 7.

218 Awan Z, Alwaili K, AlShaharani A, Goltzman D, Genest J. Calcium Homeostasis and Cortical Bone Integrity in Aortic Calcification in Subjects with Familial Hypercholesterolemia [*] Clin Chem. 2010;56(10):1599-607

219 Kramer MS, Lydon J, Séguin L, Goulet L, Kahn SR, McNamara H, Genest J, Sharma S, Meaney MJ, Libman M, Dahhou M, Platt RW. Non-stress-related factors associated with maternal corticotrophin-releasing hormone (CRH) concentration. Paediatr Perinat Epidemiol. 2010 Jul 1;24(4):390-7.

220 Goodman SG, Langer A, Bastien NR, McPherson R, Francis GA, Genest J, Leiter L. on behalf of the DYSIS Canadian Investigators. Prevalence of dyslipidemia in statin treated patients in Canada: Results of the International Dyslipidemia study (DYSIS) Can J Cardiol 2010;26:e330-35

221 Ananth CV, Getahun D, Srinivas N, DeMarco C, Elsasser D, Lai YL, Pitts S, Smulian JC, Kinzler WL, Peltier MR, Lake M, Philipp P, Rhoads GG, Moore DF, Genest J, Shen-Schwarz S, Prasad V. The Normal anticoagulant system and risk of placental abruption: protein C, protein S and resistance to activated protein C. J Matern Fetal Neonatal Med. 2010 Dec;23(12):1377-83

222 Kiss RS, You Z, Genest J, Giaid A. Urotensin II differentially regulates hepatic and macrophagic cholesterol homeostasis. Peptides. 2011;32:956-63 Mar 2. [Epub ahead of print]

223 Roifman I, Beck P, Anderson TJ, Eisenberg M, Genest J. Chronic inflammatory diseases and cardiovascular risk. [*] Can J cardiol 2011;27;174-182

224 Cardiometabolic Risk Working Group: Executive Committee, Leiter LA, Fitchett DH, Gilbert RE, Gupta M, Mancini GB, McFarlane PA, Ross R, Teoh H, Verma S; Working Group, Anand S, Camelon K, Chow CM, Cox JL, Després JP, Genest J, Harris SB, Lau DC, Lewanczuk R, Liu PP, Lonn EM, McPherson R, Poirier P, Qaadri S, Rabasa-Lhoret R, Rabkin SW, Sharma AM, Steele AW, Stone JA, Tardif JC, Tobe S, Ur E. Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). Can J Cardiol. 2011 Mar-Apr;27(2):124-31.

225 Leiter LA, Fitchett D, Gilbert RE, M Gupta, Mancini JBJ, McFarlane PA, Ross R, Teoh H, Verma S (Executive Committee), Working Group: Anand S, Camelon K, Chow C-M, Cox JL, Després JP, Genest J, Harris SB, Lau DCW, Lewanczuk R, Liu PP, Lonn EM, McPherson R, Poirier P, Qaadri S, Rabasa-Lhoret R, Rabkin SW, Sharma AM, Steele AW, Stone JA, Tardif JC, Tobe, Ur E. Identification and Management of Cardiometabolic Risk in Canada—a Position Paper by the Cardiometabolic Risk Working Group. Can J Cardiol 2011;27:124-131; e1-e33

226 Mancini JGB, Baker S, Bergeron J, Frohlich J, Fitchett D, Genest J, Gupta M, Hegele RA, Ng D,

Pope J. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J cardiol 2011;27:635-662


46

227 Alwaili K*, Bailey D*, Awan Z, Laboissiere S, Krimbou L, Genest J. The HDL proteome in acute coronary syndromes shifts to an inflammatory phenotype. [CIHR MOP 15042] [*] BBA - Molecular and Cell Biology of Lipids 2011 Accepted manuscript available online 07.2011 http://www.sciencedirect. com/science/ article/pii/ S1388198111001387

228 Iatan I, Bailey D, Ruel I, Hafiane A, Krimbou L, Genest J. Membrane microdomains modulate

oligomeric ABCA1 function: impact on apoAI-mediated lipid removal and phosphatidylcholine biosynthesis. J Lipid Res. 2011;52(11):2043-55. [*] [CIHR MOP 15042]

229 Awan Z, Denis M, Bailey D, Prat A, Goltzman D, Seidah NG, Genest J. The LDL-R Deficient Mouse

as a Model for Aortic Calcification and Quantify by micro computer tomography. Atheroscler 2011;219:455-62 published online [*] CIHR CTP 82946

230 Tobe SW, Stone JA, Brouwers M, Battacharyya O, Walker KM, Dawes M, Genest J, Grover S,

Gubitz G, Lau D, Popo A, Selby P, Tremblay MS, Warburton DER, Ward R, Woo V, Leiter LA, Liu PP. Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE initiative. CMAJ 2010;183:e113-50 on line pub. Sept 12, 2011

231 Thorogood A, Mottillo S, Shimony A, Filion KB, Joseph L, Genest J, Pilote L, Poirier P, Schiffrin EL, Eisenberg MJ. Isolated aerobic exercise and weight loss: a systematic review and meta-analysis of randomized controlled trials. Am J Med. 2011 Aug; 124(8):747-55.

232 Awan Z, Danielson E, Glyn R, Ridker PM, Seidah NG, Genest J. Rosuvastatin, PCSK9 Levels, and LDL-C Response: The JUPITER Trial. Clin Chem. 2012 Jan;58(1):183-9. Epub 2011 Nov 7.Editorial. [*]CIHR CTP 82946

233 Kahn SR, Almeida N, McNamara H, Koren G, Genest J, Dahou M, Platt R, Kramer MS. Smoking in

preeclamptic women is associated with higher birthweight for gestational age and lower soluble fms-like tyrosine kinase-1 levels. BMC Pregnancy and Childbirth 2011:11;91

234 Friedland SN, Leong A, Filion KB, Genest J, Lega IC, Mottillo S, Poirier P, Reoch J, Eisenberg MJ.

The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor Agonists. Am J Med. 2012 Feb;125(2):126-33

235 Lee C-Y, Ruel I, Denis M, Genest J, Kiss RS. Cholesterol trapping in the endosomal pathway does not impair cholesterol efflux in Niemann-Pick disease type B fibroblasts. [CIHR MOP 15042; CIHR 97752 and HSFC] [*]. J Clin Lipidol Accepted 02.1012

236

Submitted • Linga-Reddy MVP* Iatan I*, Weissglas-Volkov D, Nokkola E, Haas B, Sinsheimer J, Genest J,

Pajukanta P. Exome sequencing identifies two rare variants for low HDL-C in an extended family. Submitted Dec 2011 Am J Hum Genet [*] [CIHR MOP 97752; HSCF]

• Iatan I, Palmyre A, Alrasheed S, Ruel I, Genest J. Genetic of cholesterol efflux. Curr Atheroscler.

Reports 2012 (Invited review) [†] [*] [CIHR MOP 97752; HSCF]

In Preparation • Alrasheed S, Hafiane A, Bailey D, Ruel I, Genest J. cellular cholesterol efflux in Familial HDL

Deficiency.

• You Z, Genest J, Barrette PO, Behm DJ, D’Orleans-Juste P#, Giaid A*. Role of Urotensin II in atherosclerosis. Submitted Circulation 2011

• Wakil SM, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin E, Eisenberg MJ A Meta-Analysis of the Effect of Weight Loss Pharmacotherapies on Cardiovascular Risk Factors.


47

• Evidence of confounding by prescribing practices in a cluster randomized trial evaluation of a physician-pharmacist collaborative care model for the management of dyslipidemia. Lalonde L, Blais L, Berbiche B, Villeneuve J, Perreault S, Genest J, Hudon E, Vanier MC, Lamarre D. Journal of the Society for Clinical Trials. 07.2011

• Friedland SN, Leong A, Filion KB, Berry EM, Genest J, Lega IC, Mottillo S, Poirier P, Reoch J, Eisenberg MJ. The Cardiovascular Effects of Peroxisome Proliferator-Activated Receptor Agonists. Submitted Am J Med 08.2011

• Lalonde L, Blais L, Berbiche B, Villeneuve J, Perreault S, Genest J, Hudon E, Vanier MC, Lamarre D. Evaluation of a collaborative care model: Confounding bias and participation effect in a primary care cluster randomized controlled trial. Submitted BMJ/2010/806729

Book Chapters, Books 1. Genest J Jr. Physicians’ Guide to the Management of Lipoprotein Disorders (book). 1990 STA

Communications, Montréal, Canada (English/French) ISBN 0-919391-14-I 2. Genest J Jr. Postmyocardial infarction risk factor modification: dyslipoproteinemias. In: Evidence

Based Cardiology. Yusuf S, Cairns JA, Camm AJ, Fallen E, Gersh BJ. (eds) BMJ Books 1998 pp1063-66 [book chapter]

3. Guide Thérapeutique de l’Hypertension Artérielle. Société Québécoise d’hypertension arterielle.

Cartier P, Chiasson J-L, Dagenais GR, de Champlain J, Drouin D, Gagné C, Gaudet D, Genest J Jr. et al. 1999. ISBN 2-98066257-0-1

4. Genest J Jr, Cohn JS. Epidemiological evidence linking plasma lipoprotein disorders to

atherosclerosis and other diseases. In: Advances in Vascular Biology series; Plasma lipids and their role in disease (Chapter 3). P. Barter, K-A Rye eds. Harwood Academic Publishers. [book chapter] p45-68, 1999

5. Genest J. Jr. Familial Disorders of Homocysteine [Book Chapter, Homocysteine and Vascular

Disease. Kluwer Academic Publishers. K. Robinson, ed.] 2000 pp 203-216 6. Ridker P, Genest J Jr, Libby P. Plasma lipids and lipoproteins and cardiovascular diseases. In:

Braunwald’s Heart Disease. Braunwald E, Libby P, Zipes D, Editors. 2000;1010-1039. Saunders, New York

7. Guide Thérapeutique de l’Hypertension Artérielle. Société Québécoise d’hypertension arterielle.

Cartier P, Chiasson J-L, Couture G, Dagenais GR, de Champlain J, Drouin D, Gagné C, Gaudet D, Genest J Jr. et al. 2002. ISBN 2-98066257-1-X

8. Genest J Jr. High Risk and Secondary Prevention of Coronary Artery Disease. In: Cairns JA, Camm

J, Fallen E, Gersh B, Yusuf S. Evidence-Based Cardiology. BMJ Books. Second Edition. 2002 9. Genest J. Novel Risk Factors for Coronary artery Disease (Chapter 9). In Theroux: Acute Coronary

Syndromes: A companion to Braunwald’s Heart Disease. Braunwald E, Theroux P, Editors. Saunders, New York 2003; pp119-130

10. Genest J, Gotto A, Libby P. Lipoprotein Disorders and CAD (Chapter 39). Braunwald’s Heart

Disease. Braunwald E, Libby P, Zipes D, Editors. 2004. Saunders, New York, pp 1013-1033 11. Stone JA, Arthur H, Drouin D, Feldman R, Fodor G, Friesen M, Genest J, Gledhill N, Harris S,

Katzmarzyk P, Leiter L, Prior P, Sharratt. Chapter 8: Risk factor modification and secondary prevention in: Canadian Guidelines for Cardiac Rehabilitation and CVD Prevention. 2004 pp 115-191 ISBN 0-9685851-2-4


48

12. Genest J, Libby P. Lipoprotein Disorders and CAD (Chapter 42). Braunwald’s Heart Disease. Braunwald E, Libby P, Zipes D, Bonow R, Editors. 2007. Saunders, New York,

13. Genest J, Dastani Z, Engert J, Marcil M. Chapter 17: Genetics of High Density Lipoproteins. In: High-

density lipoproteins: from basic biology to clinical aspects. Fielding CJ. 2007 Wiley-VCH Editors, Weinheim, Germany pp 465-490

14. Genest J. Treatment of dyslipidemias for cardiovascular disease prevention. In: Cardiovascular

Biology in Health and Disease. Haegerty A, Schiffrin Eds. 2007 15. James A Stone, Norm R Campbell, Jacques Genest, Stewart Harris, Andrew Pipe, Dareen E.

Warburton. Health behaviour interventions and cardiovascular disease risk factor modification in primary and secondary event prevention. Chapter 9 CACR. Guidelines for Cardiac Rehabilitation and CVD Prevention. 2009

16. AlWaili K, Alrasadi K, Awan Z, Iatan I, Dastani Z, Genest J. Genetic Lipoprotein Disorders and

Cardiovascular Diseases. In: Genetics of Cardiovascular Diseases. Springer-Verlag Eds, 2010 17. Genest J Jr. Metabolic Risk and Post Myocardial Infarction Management: Low High-Density

lipoprotein cholesterol (HDL-C) post myocardial infarction In: Evidence Based Cardiology. Yusuf S, Cairns JA, Camm AJ, Fallen E, Gersh BJ. (eds) BMJ Books 2010 [chapter 75]

18. Genest J, Ridker PM, Libby P. Chapter 47: Lipoprotein Disorders and CAD. Braunwald’s Heart

Disease 9th Edition. Braunwald E, Libby P, Zipes D, Bonow R, Editors. 2011. Saunders, New York, Reviews and Other Publications, non peer-reviewed 1. Genest J Jr. Treatment of lipid disorders in patients with coronary artery disease. Drug Protocol 1989;4:9-16

2. Genest J Jr. Managing lipid disorders in patients with CAD. Cardiology Consultant 1990;1:14-25

3. Genest J Jr. Familial Combined Hyperlipidemia. Can. J. Lipidology 1991;3:18 *

4. Genest J Jr. Jacynthe Touchette, Colette Rondeau. Prévention secondaire: les lipides et le patient coronarien.

Médecine Moderne 1991;46:8-15 †

5. Boyer H, Genest J. Jr. Lipoprotein disorders: a practical approach. Can. J. Diag. 1991;8:66-84

6. Laurier D, Prevost D, Mailloux M, Genest J Jr. Cholestérol et nutrition, au delà du dépliant. Le Médecin du Québec 1992;27:31-65

7. Genest J Jr. Metabolic factors in atherosclerosis: a cardiologist's point of view. Focus on dyslipidemias

(1993;2:3)

8. Genest J Jr. Hypertension arterielle et dyslipoproteinemie: prevention de la maladie coronarienne. Actualité medicale 1994 18 Mai, p4

9. Genest J Jr, M Francoeur RN. Diabetes and coronary artery disease: is regression possible. Plein Soleil.

Canadian Diabetes Association Publication, Spring 1994. †

10. Scientific Advisory Committee, Coronary Health Assessment Study [CHAS]. Steven A Grover (PI) et al. Do doctors assess coronary risk in their patients? Preliminary results of the Coronary Health Assessment Study. Br Med J 1995;310:975-978

11. Genest J Jr. Le traitement de la maladie coronarienne athéroscléreuse. Cholestaction. Actualité Médicale 1996

12. Wolchuck LN, Genest J Jr., Leiter LA. When and how to use lipid-lowering drugs. Patient Care 1995;6:18-26

13. Leiter L, Fodor G, Genest J Jr., Sniderman A, Tremblay G. Coronary heart disease prevention: the role of HMG

CoA reductase inhibitors. Perspectives in Cardiology 1996;1:1-11

14. Genest J Jr. Le diagnostic et traitement des dyslipoproteinemies. L’Omnipraticien. Sept 1996:1-3


49

15. Genest J Jr. Le pontage aorto-coronarien. Revue Plein Soleil Sept 1996

16. Genest J Jr. The need for identifying high-risk individuals in primary prevention. (case repport) Raven Press

1997.

17. Genest J Jr. Diagnosis and treatment of hypercholesterolemia and other dyslipidemias. The Medical Post 1997, July

18. Genest J. Jr. Reaching a new consensus on cholesterol. Cardiology 1997;13:15-17

19. Genest J. Jr. Letter to the Editor, Can J Cardiol 1997;13:729 (reply)

20. Genest J. Jr. Le diagnostic et traitement de l'hypercholesterolemie et autres dyslipidemies. L'Omnipraticien

1997

21. Genest J. Jr. Diagnosis and treatment of hyperlipidemias. Perspectives in Cardiology 1997;13:15-17

22. Genest J. Jr. Le traitement de l'hyperlipidémie chez le coronarien. Journees du departement de medecine, U de M L'Omnipraticien 30 sept. 1998

23. Johnes PH On behalf of the CURVES investigators. (Genest J Jr. PI, Montreal site). Comparison of the dose

efficacy of atorvastatin with pravastatin, simvastatin, fluvastatin and lovastatin - the CURVES study. Am J Cardioll 1998;81:582-587

24. McLaughlin PR, Gladstone P. for the DAIS Project Group. (Genest J Jr, PI, Montreal site) Diabetes

Atherosclerosis Intervention Study (DAIS): quantitative coronary angiographic analysis of coronary artery atherosclerosis. Catherer Cardiovasc Diag 1998;44:249-256

25. Crouse JR, Frohlich J, Ose L, Mercuri M, Tobert JA. Effects of high doses of simvastatin and atorvastatin on

high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol. 1999 May 15;83(10):1476-7, A7. (Genest J Jr, PI, Montreal site)

26. Genest J Jr. Traitement hypolipidémiant: jusqu’au faut-il abaisser les lipides. Le Clinicien, 1999

27. Genest J Jr. Traitement des Dyslipidémies. Cancun Symposium, 1999

28. Genest J, McPherson R. Physician perspective (Medical Education Network). Significant changes in the new

guidelines for the management of lipid disorders. 2000.

29. Genest J. Novel Risk Factors for CAD. Issues in Lipidol 2001;4:9-15 [*].

30. Genest J, Habib R. Hypertension artérielle, diabète et risque de maladie coronarienne atheroscléreuse. L’actualité médicale, 2003vv

31. Genest J. Annual Cardiovascular Conference Proceedings. Novel Markers of CAD : Inflammation and Genetics

Klinke P, Warnica eds. 2002 ;35 :43 32. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang C-H, Stampfer

M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. The Vitamin Intervention for Stroke Prevention (VISP) randomized clinical trial. J Am Med Ass 2004;291:565-576. J. Genest, coronary end point review committee

33. Feldman R, Genest J. Global risk assessment in 2005: Where de we stand. Expert Opinions Clinical Impact

2005;1(7) 3-5 34. Genest J. Mechanisms and Cardiovascular Complications of Obesity” CD-ROM Chapter 2, “Obesity

and Cardiovascular Disease”. Mechanisms in clinical cardiology 2006 35. Stone JA, Austford L, Parker JH, Gledhill N, Trembaly G, Arthur HM, Campbell N, Drouin D, Feldman

R, Fodor G, Gagnon R, Genest J, Harris S, Leiter L, Pipe A, Sharratt M. Agreeing on Canadian cardiovascular practice guidelines. Can J Cardiol (Accepted Aug 2007)


50

36. Genest J, Francis G, Cernew G. Emerging clinical science from the 2007 scientific sessions of the

American Heart Association. McGill University CME program 2008 37. Genest J, Abrahamson B, Anderson T, Davignon J, Fort S, McPherson R, Verma S. The clinical

impact of JUPITER. Journal Club in Cardiology. MedNet.ca 2009

38. Genest J, Krimbou L, Wong N. RVX-208: a small molecule that increases HDL. Future Medicine 2010

39. Mora S, Glynn RJ, Hsia J, Macfadyen JG, Genest J, Ridker PM.Response to letter regarding article,

"Statins for the Primary Prevention of Cardiovascular Events in Women with Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia. Results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women from Primary Prevention Trials" Circulation. 2010 Dec 7;122(23

40. Ckarke R et al. Homocysteine and CHD: meta-analysis of MTHFR case-control studies, avoiding publication bias. (Genest J Collaborator) Plos Medicine 2012;9:e10001177

Editorials 1. Genest J Jr. Lipoprotein(a): current status, future prospects. (Editorial) Can. J. Cardiol. 1990;6:IX

2. Genest J Jr. Familial Combined Hyperlipidemia. (Editorial) Can. J. Cardiol. 1991;7:X-XI; Can. Med. Ass. J.

1991;145:664

3. Genest J Jr. Cholestérol: Aspects génétiques. Éditorial, Union Médicale du Can. Français, 1993 Mai/Juin, p 160.

4. Genest J Jr. Prevention and treatment of coronary artery disease: A tale of two approaches. Editorial, Medica

Illustrata 1994.

5. Genest J Jr. Editorial. Patient Care 1994

6. J. Genest Jr, J. Frolich. Editors, Symposium on Lipoproteins, coagulation factors and diabetes; Major risk factors for coronary artery disease. A time to work, a time to teach, a time to learn. Editorial. Can J Cardiol May 1994

7. Genest J Jr. Editorial. Treatment of dyslipoproteinemias. Perspectives in Cardiology. 1995

8. Genest J Jr., Audelin M-C, Lonn E. Homocysteine: To screen and treat or to wait and see. Can Med Ass J.

2000;163;37-8 [Editorial]

9. Genest J. Ad-hoc consultant, WebMD, 2001

10. Genest J Jr. Cardiology Abstracts in Perspective. Additional Vascular Benefits of Statin Therapy (Editorial). 2002 ;1 :2-5

11. Genest J. Watching Sports or doing sports : children’s investment in cardiovascular health (Editorial). Can J

Cardiol 2004;20:303-4 12. Genest J et al. Towards a common goal: harmonizing Canadian risk assessment and treatment guidelines. Can

J Cardiol 2004; ●●●;●●-●● 13. Genest J. JUPITER: the first landmark CRP-driven trial. Expert Opinions: clinical impact 2004;1(3)13-14 14. Genest J. The Yin and the Yang of HDL-C. Editorial. J Am Coll Cardiol 2008;51:643-4

Abstracts: Approximately 275-300


51

CURRICULUM VITAE IDENTIFICATION - … VITAE IDENTIFICATION Jacques Genest MD FRCP(C) Scientific...

Documents

Transcript of CURRICULUM VITAE IDENTIFICATION - … VITAE IDENTIFICATION Jacques Genest MD FRCP(C) Scientific...